US20050014760A1 - Methods of treating diseases or conditions using dihydropteridinone compounds - Google Patents

Methods of treating diseases or conditions using dihydropteridinone compounds Download PDF

Info

Publication number
US20050014760A1
US20050014760A1 US10/903,807 US90380704A US2005014760A1 US 20050014760 A1 US20050014760 A1 US 20050014760A1 US 90380704 A US90380704 A US 90380704A US 2005014760 A1 US2005014760 A1 US 2005014760A1
Authority
US
United States
Prior art keywords
alkyl
aryl
denotes
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/903,807
Inventor
Matthias Hoffmann
Matthias Grauert
Trixi Brandl
Steffen Breitfelder
Christian Eickmeier
Martin Steegmaier
Gisela Schnapp
Anke Baum
Jens Quant
Flavio Solca
Florian Colbatzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to US10/903,807 priority Critical patent/US20050014760A1/en
Publication of US20050014760A1 publication Critical patent/US20050014760A1/en
Priority to US11/219,945 priority patent/US7786299B2/en
Priority to US12/129,728 priority patent/US7816530B2/en
Priority to US12/873,687 priority patent/US8003786B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Definitions

  • the present invention relates to new dihydropteridinones of general formula (I) wherein the groups L, R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
  • Pteridinone derivatives are known from the prior art as active substances with an antiproliferative activity.
  • WO 01/019825 describes the use of pteridinone derivatives for the treatment of neoplastic and viral diseases.
  • the resistance of many types of tumours calls for the development of new pharmaceutical compositions for combating tumours.
  • the aim of the present invention is to prepare new compounds with antiinflammatory and antiproliferative activity.
  • compounds of general formula (I) wherein the groups L and R 1 to R 5 have the meanings given hereinafter act as inhibitors of specific cell cycle kinases.
  • the compounds according to the invention may be used for example to treat diseases connected with the activity of specific cell cycle kinases and characterised by excessive or abnormal cell proliferation.
  • the present invention therefore relates to compounds of general formula (I) wherein
  • Preferred compounds of formula (I) are those wherein
  • the invention further relates to compounds of formula I for use as pharmaceutical compositions.
  • the invention also relates to the use of a compound of formula I for preparing a pharmaceutical composition for the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.
  • the invention also relates to a method of treating and/or preventing cancer, infections, inflammatory and autoimmune diseases, characterised in that a patient is given an effective amount of a compound of formula I.
  • the invention also relates to pharmaceutical preparations, containing as active substance one or more compounds of general formula (I) or the physiologically acceptable salts thereof, optionally combined with conventional excipients and/or carriers.
  • the invention also relates to a process for preparing a compound of general formula (I), wherein
  • the invention further relates to a compound of formula (II), wherein
  • alkyl groups including alkyl groups which are a part of other groups, denotes branched and unbranched alkyl groups with 1 to 12 carbon atoms, preferably 1-6, most preferably 1-4 carbon atoms, such as, for example: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl.
  • propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl include all the possible isomeric forms.
  • propyl includes the two isomeric groups n-propyl and iso-propyl
  • butyl includes n-butyl, iso-butyl, sec. butyl and tert.-butyl
  • pentyl includes iso-pentyl, neopentyl, etc.
  • one or more hydrogen atoms may optionally be replaced by other groups.
  • these alkyl groups may be substituted by fluorine. All the hydrogen atoms of the alkyl group may optionally also be replaced.
  • alkyl bridge denotes branched and unbranched alkyl groups with 1 to 5 carbon atoms, for example methylene, ethylene, propylene, isopropylene, n-butylene, iso-butyl, sec. butyl and tert.-butyl etc. bridges. Methylene, ethylene, propylene and butylene bridges are particularly preferred.
  • 1 to 2 C-atoms may optionally be replaced by one or more heteroatoms selected from among oxygen, nitrogen or sulphur.
  • alkenyl groups denotes branched and unbranched alkylene groups with 2 to 10 carbon atoms, preferably 2-6 carbon atoms, most preferably 2-3 carbon atoms, provided that they have at least one double bond. Examples include: ethenyl, propenyl, butenyl, pentenyl etc. Unless otherwise stated, the abovementioned terms propenyl, butenyl, etc also include all the possible isomeric forms.
  • butenyl includes 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl and 1-ethyl-1-ethenyl.
  • one or more hydrogen atoms may optionally be replaced by other groups.
  • these alkyl groups may be substituted by the halogen atom fluorine. All the hydrogen atoms of the alkenyl group may optionally also be replaced.
  • alkynyl groups denotes branched and unbranched alkynyl groups with 2 to 10 carbon atoms, provided that they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl etc., preferably ethynyl or propynyl.
  • one or more hydrogen atoms may optionally be replaced by other groups.
  • these alkyl groups may be substituted by fluorine. All the hydrogen atoms of the alkynyl group may optionally also be replaced.
  • aryl denotes an aromatic ring system with 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, preferably phenyl, which, unless otherwise stated, may carry one or more of the following substituents, for example: OH, NO 2 , CN, OMe, —OCHF 2 , —OCF 3 , —NH 2 , halogen, for example fluorine or chlorine, C 1 -C 10 -alkyl, preferably C 1 -C 5 -alkyl, preferably C 1 -C 3 -alkyl, most preferably methyl or ethyl, —O—C 1 -C 3 -alkyl, preferably —O-methyl or —O-ethyl, —COOH, —COO—C 1 -C 4 -alkyl, preferably —O-methyl or —O-ethyl, —CONH 2 .
  • heteroaryl groups wherein up to two carbon atoms are replaced by one or two nitrogen atoms include pyrrole, pyrazole, imidazole, triazole, pyridine, pyrimidine, while each of the abovementioned heteroaryl rings may optionally also be anellated to a benzene ring, preferably benzimidazole, and unless otherwise stated these heterocycles may carry one or more of the following substituents, for example: F, Cl, Br, OH, OMe, methyl, ethyl, CN, CONH 2 , NH 2 , optionally substituted phenyl, optionally substituted heteroaryl, preferably optionally substituted pyridyl.
  • cycloalkyl groups are cycloalkyl groups with 3-12 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl, while each of the abovementioned cycloalkyl groups may optionally also carry one or more substituents, for example: OH, NO 2 , CN, OMe, —OCHF 2 , —OCF 3 , —NH 2 or halogen, preferably fluorine or chlorine, C 1 -C 10 -alkyl, preferably C 1 -C 5 -alkyl, preferably C 1 -C 3 -alkyl, more preferably methyl or ethyl, —O—C 1 -C 3 -alkyl, preferably —O-methyl or —O-eth
  • cycloalkenyl groups are cycloalkyl groups with 3-12 carbon atoms which have at least one double bond, for example cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, preferably cyclopropenyl, cyclopententyl or cyclohexenyl, while each of the abovementioned cycloalkenyl groups may optionally also carry one or more substituents.
  • ⁇ O denotes an oxygen atom linked via a double bond.
  • heterocycloalkyl groups include 3- to 12-membered, preferably 5-, 6- or 7-membered, saturated or unsaturated heterocycles which may contain as heteroatoms nitrogen, oxygen or sulphur, for example tetrahydrofuran, tetrahydrofuranone, ⁇ -butyrolactone, ⁇ -pyran, ⁇ -pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolan, dithiolan, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepan, oxazine, tetrahydro-ox
  • polycycloalkyl groups are optionally substituted, bi-, tri-, tetra- or pentacyclic cycloalkyl groups, for example pinane, 2,2,2-octane, 2,2,1-heptane or adamantane.
  • polycycloalkenyl groups are optionally bridged and/or substituted 8-membered bi-, tri-, tetra- or pentacyclic cycloalkenyl groups, preferably bicycloalkenyl or tricycloalkenyl groups, if they have at least one double bond, for example norbornene.
  • spiroalkyl groups are optionally substituted spirocyclic C 5 -C 12 alkyl groups.
  • halogen denotes fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, most preferably chlorine.
  • the leaving group A denotes either identical or different leaving groups such as for example -o-methyl, —SCN, chlorine, bromine, iodine, methanesulphonyl, trifluoromethanesulphonyl or p-toluenesulphonyl, preferably chlorine.
  • the compounds according to the invention may be present in the form of the individual optical isomers, mixtures of the individual enantiomers, diastereomers or racemates, in the form of the tautomers and also in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids—such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
  • pharmacologically acceptable acids such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
  • the substituent R 1 may denote hydrogen or a group selected from among optionally substituted and/or branched C 1 -C 6 -alkyl, preferably methyl or ethyl, more preferably methyl or ethyl.
  • the substituent R 2 may denote hydrogen or a group selected from among optionally substituted and/or branched C 1 -C 6 -alkyl, preferably methyl or ethyl.
  • R 1 and R 2 together may denote a 2- to 5-membered alkyl bridge, preferably an ethylene, propylene or butylene bridge which may contain 1 to 2 heteroatoms, preferably oxygen or nitrogen, more preferably ethylene, propylene.
  • the substituent R 3 may denote hydrogen or a group selected from among optionally substituted and/or branched C 1 -C 12 -alkyl, preferably ethyl, propyl, butyl, pentyl or hexyl, more preferably propyl, butyl, pentyl or hexyl, C 2 -C 12 -alkenyl, preferably C 5 -C 7 -alkenyl, C 2 -C 12 -alkynyl, preferably C 5 -C 7 -alkynyl and C 6 -C 14 -aryl, preferably phenyl, a group selected from among optionally substituted and/or bridged C 3 -C 12 -cycloalkyl, preferably cyclopentyl or cyclohexyl, C 3 -C 12 -cycloalkenyl, preferably C 5 -C 7 -cycloalkenyl, C 7 -C 12 -polycycloal
  • the substituent R 3 denotes isopropyl, isobutyl, isopentyl, cyclopentyl, phenyl or cyclohexyl.
  • R 1 and R 3 or R 2 and R 3 together may denote a saturated or unsaturated C 3 -C 4 -alkyl bridge which may contain 1 heteroatom, preferably oxygen or nitrogen.
  • the substituent R 4 may denote a group selected from among hydrogen, —CN, hydroxy, —NR 6 R 7 and Halogen, preferably chlorine or fluorine, more preferably chlorine or a group selected from among optionally substituted C 1 -C 6 -alkyl, preferably methyl, ethyl or propyl, C 2 -C 6 -alkenyl, preferably ethenyl or propenyl, C 2 -C 6 -alkynyl, preferably ethynyl, propynyl or butynyl, C 1 -C 5 -alkyloxy, preferably methoxy, ethoxy or propargyloxy, C 2 -C 5 -alkenyloxy, C 2 -C 5 -alkynyloxy, C 1 -C 6 -alkylthio, C 1 -C 6 -alkylsulphoxo and C 1 -C 6 -alkylsulphonyl.
  • the substituent R 4 denotes methoxy, methyl, ethoxy, ethyl, propargyloxy or chlorine.
  • L may denote a linker selected from among optionally substituted C 2 -C 10 -alkyl, preferably ethyl, propyl, butyl or pentyl, C 2 -C 10 -alkenyl, C 6 -C 14 -aryl, preferably phenyl, —C 2 -C 4 -alkyl-C 6 -C 14 -aryl, —C 6 -C 14 -aryl-C 1 -C 4 -alkyl, preferably -phenyl-methyl optionally bridged C 3 -C 12 -cycloalkyl, preferably cyclohexyl, and heteroaryl which contains 1 or 2 nitrogen atoms.
  • C 2 -C 10 -alkyl preferably ethyl, propyl, butyl or pentyl
  • C 2 -C 10 -alkenyl C 6 -C 14 -aryl, preferably phenyl, —C 2 -C 4
  • R 5 may denote a group selected from among optionally substituted morpholinyl, piperidinyl, piperazinyl, piperazinylcarbonyl, pyrrolidinyl, tropenyl, R 8 -diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, —NR 8 R 9 and azacycloheptyl, preferably piperidinyl, morpholinyl, pyrrolidinyl, sulphoxomorpholiny, piperazinyl, thiomorpholinyl or tropenyl.
  • the groups R 6 and R 7 may be identical or different and may denote hydrogen or C 1 -C 4 -alkyl, preferably methyl or ethyl.
  • the groups R 8 and R 9 may be unsubstituted nitrogen substituents at R 5 , they may be identical or different and denote either hydrogen or a group selected from among C 1 -C 6 -alkyl, preferably methyl, ethyl or propyl, —C 1 -C 4 -alkyl-C 3 -C 10 -cycloalkyl, preferably —CH 2 -cyclopropyl, C 3 -C 10 -cycloalkyl, C 6 -C 14 -aryl, preferably phenyl, —C 1 -C 4 -alkyl-C 6 -C 14 -aryl, preferably benzyl, pyranyl, pyridinyl, pyrimidinyl, pyranyl, C 1 -C 4 -alkyloxycarbonyl, C 6 -C 14 -arylcarbonyl, C 1 -C 4 -alkylcarbonyl, C 6 -C 14 -aryl
  • the substituent R 8 denotes methyl, ethyl or propyl.
  • the substituent R 9 denotes methyl, ethyl or propyl.
  • R 10 may be a substituent selected from among OH, NH2-LR5, —O-methyl and —O-ethyl, preferably OH, LR5, —O-methyl or —O-ethyl.
  • R 1 to R 10 may optionally be branched and/or substituted.
  • the compounds according to the invention may be prepared by synthesis methods A described hereinafter, while the substituents of general formulae (A1) to (A9) have the meanings given hereinbefore. This method is to be understood as an illustration of the invention without restricting it to the subject matter thereof.
  • a compound of formula (A1) is reacted with a compound of formula (A2) to obtain a compound of formula (A3) (Diagram 1A).
  • This reaction may be carried out according to WO 0043369 or WO 0043372.
  • Compound (A1) is commercially obtainable, for example, from City Chemical LLC, 139 Allings Crossing Road, West Haven, Conn., 06516, USA.
  • Compound (A2) may be prepared by procedures known from the literature: (a) F. Effenberger, U. Burkhart, J. Willfahrt Liebigs Ann. Chem. 1986, 314-333; b) T. Fukuyama, C.-K. Jow, M. Cheung, Tetrahedron Lett.
  • Step 1A 1 equivalent of the compound (A1) and 1 to 1.5 equivalents, preferably 1.1 equivalents of a base, preferably potassium carbonate, potassium hydrogen carbonate, sodium carbonate or sodium hydrogen carbonate, calcium carbonate, most preferably potassium carbonate, are stirred in a diluent optionally mixed with water, for example acetone, tetrahydrofuran, diethylether, cyclohexane, petroleum ether or dioxane, preferably cyclohexane or diethylether.
  • a base preferably potassium carbonate, potassium hydrogen carbonate, sodium carbonate or sodium hydrogen carbonate, calcium carbonate, most preferably potassium carbonate
  • Step 2A 1 equivalent of the nitro compound (A3) is dissolved in an acid, preferably glacial acetic acid, formic acid or hydrochloric acid, preferably glacial acetic acid, and heated to 50 to 70° C. preferably about 60° C. Then a reducing agent, for example zinc, tin or iron, preferably iron filings, is added to complete the exothermic reaction and the mixture is stirred for 0.2 to 2 hours, preferably 0.5 hours, at 100 to 125° C., preferably at about 117° C. After cooling to ambient temperature the iron salt is filtered off and the solvent is distilled off.
  • an acid preferably glacial acetic acid, formic acid or hydrochloric acid, preferably glacial acetic acid
  • a reducing agent for example zinc, tin or iron, preferably iron filings
  • the residue is taken up in a solvent or mixture of solvents, for example ethyl acetate or dichloromethane/methanol 9/1 and semisaturated NaCl solution, and filtered through kieselgur, for example.
  • the organic phase is dried and evaporated down.
  • the residue (compound (A4)) may be purified by chromatography or by crystallisation or used as the crude product in Step 3A of the synthesis.
  • Step 2A The compound obtained in Step 2A (A4) may be reacted by electrophilic substitution as shown in Diagram 3A to obtain the compound of formula (A5).
  • Diagram 3A The compound obtained in Step 2A (A4) may be reacted by electrophilic substitution as shown in Diagram 3A to obtain the compound of formula (A5).
  • Step 3A 1 equivalent of the amide of formula (A4) is dissolved in an organic solvent, for example dimethylformamide or dimethylacetamide, preferably dimethylacetamide, and cooled to about ⁇ 5 to 5° C., preferably 0° C. Then 0.9 to 1.3 equivalents of sodium hydride and 0.9 to 1.3 equivalents of a methylating reagent, e.g. methyl iodide, are added.
  • the reaction mixture is stirred for 0.1-3 hours, preferably about 1 hour, at about 0 to 10° C., preferably at about 5° C., and may optionally be left to stand for a further 12 hours at this temperature.
  • the reaction mixture is poured onto ice water and the precipitate is isolated.
  • the residue (compound (A5)) may be purified by chromatography, preferably over silica gel, or by crystallisation, or used as the crude product in step 4A of the synthesis.
  • 1 equivalent of the compound (A5) and 1 to 3 equivalents, preferably about 2 equivalents of the compound (A6) are heated without a solvent or in an organic solvent such as for example sulpholane, dimethylformamide, dimethylacetamide, toluene, N-methylpyrrolidone, dimethylsulphoxide or dioxane, preferably sulpholane, for 0.1 to 4 hours, preferably 1 hour, at 100 to 220° C., preferably at about 160° C.
  • the product (A9) is crystallised by the addition of organic solvents or mixtures of solvents, e.g. diethylether/methanol, ethyl acetate, methylene chloride, or diethylether, preferably diethylether/methanol 9/1, or purified by chromatography.
  • 1 equivalent of the compound (A5) and 1 to 3 equivalents of the compound (A6) are stirred with acid, for example 1-10 equivalents of 10-38% hydrochloric acid and/or an alcohol, for example ethanol, propanol, butanol, preferably ethanol, at reflux temperature for 1 to 48 hours, preferably about 5 hours.
  • acid for example 1-10 equivalents of 10-38% hydrochloric acid and/or an alcohol, for example ethanol, propanol, butanol, preferably ethanol, at reflux temperature for 1 to 48 hours, preferably about 5 hours.
  • acid for example 1-10 equivalents of 10-38% hydrochloric acid and/or an alcohol, for example ethanol, propanol, butanol, preferably ethanol, at reflux temperature for 1 to 48 hours, preferably about 5 hours.
  • alcohol for example ethanol, propanol, butanol, preferably ethanol
  • the product precipitated (A9) is filtered off and optionally washed with water, dried and crystallised from a suitable organic solvent.
  • a solvent for example toluene or dioxane and combined with a phosphine ligand, for example 2,2′-bis-(diphenylphosphino)-1,1′-binaphthyl and a palladium catalyst, for example tris(dibenzylidene-acetone)-dipalladium(0) and a base, for example caesium carbonate, and refluxed for 1-24 h, preferably 17 h.
  • the reaction mixture is purified for example over silica gel and the product (A8) is isolated from the solution or obtained by suitable crystallisation.
  • the product (A8) is dissolved in a suitable solvent, for example dioxane and mixed with acid, for example semiconcentrated hydrochloric acid, for example in the ratio of solvent to acid of 3:1. Then the mixture is refluxed for 1-48 h, for example 12 h, and the precipitate formed is isolated. If desired the product (A9) is purified by crystallisation.
  • a suitable solvent for example dioxane and mixed with acid, for example semiconcentrated hydrochloric acid, for example in the ratio of solvent to acid of 3:1.
  • acid for example semiconcentrated hydrochloric acid
  • an activating reagent e.g. O-benzotriazolyl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and a base, for example 1.5 equivalents of diisopropylethylamine (DIPEA) in an organic diluent, for example dichloromethane, tetrahydrofuran, dimethylformamide, N-methylpyrrolidone, dimethylacetamide, preferably dichloromethane or dimethylformamide.
  • DIPEA diisopropylethylamine
  • organic diluent for example dichloromethane, tetrahydrofuran, dimethylformamide, N-methylpyrrolidone, dimethylacetamide, preferably dichloromethane or dimethylformamide.
  • the reaction mixture is stirred for 0.1 to 24 hours, preferably about 2 hours at 20° C. to 100° C.
  • the product of formula (A11) is obtained for example by crystal
  • Example 188 and Example 203 first of all an intermediate compound Z2 is prepared as described below.
  • trans-dibenzyl-4-morpholino-cyclohexylamine may be prepared by the following method:
  • the cis isomer can be prepared analogously.
  • the cis isomer may be prepared analogously.
  • the cis isomer may be prepared analogously.
  • the faster eluting cis compound crystallised from ethyl acetate.
  • the trans-compound was crystallised from ethanol+conc. HCl. Yield: 8.5 g (61%) cis-isomer and 2.2 (13%) trans-isomer.
  • the trans-isomer may be prepared analogously.
  • Example 232 60 mg of the compound of Example 232 was dissolved in 10 mL ethyl acetate and stirred with 1 mL of acetic anhydride and 1 mL of triethylamine for 30 min. at RT. The solvent was eliminated in vacuo, the residue combined with water and ammonia, the crystals precipitated were suction filtered and washed with water and a little cold acetone. Yield: 40 mg; m.p.248° C.
  • the compounds of general formula (I) are characterised by their wide range of applications in the therapeutic field. Particular mention should be made of those applications in which the inhibition of specific cell cycle kinases, particularly the inhibiting effect on the proliferation of cultivated human tumour cells but also the proliferation of other cells, such as endothelial cells, for example, plays a part.
  • the inhibition of proliferation brought about by the compounds according to the invention is mediated by the arrest of the cells, particularly at the G2/M phase of the cell cycle.
  • the cells arrest, independently of the cells used, for a specific length of time in this phase of the cell cycle before programmed cell death is initiated.
  • An arrest in the G2/M phase of the cell cycle is triggered, for example, by the inhibition of specific cell cycle kinases.
  • Studies in model organisms such as Schizosaccharomyces pombe or Xenopus, or investigations in human cells have shown that the transition from the G2 phase to mitosis is regulated by the CDK1/cyclin B kinase (Nurse, 1990).
  • This kinase which is also known as the “mitosis promoting factor” (MPF)
  • MPF mitochondria promoting factor
  • a murine cell line with a temperature-sensitive CDK1 kinase mutant shows a rapid breakdown of the CDK1 kinase and a subsequent arrest in the G2/M phase after a temperature increase (Th'ng et al., 1990).
  • the treatment of human tumour cells with inhibitors against CDK1/cyclin B such as e.g. butyrolactone also leads to an arrest in the G2/M phase and subsequent apoptosis (Nishio, et al. 1996).
  • polo-like kinase 1 Another kinase which is involved in the G2 and mitosis phase is polo-like kinase 1 (Plk1), which is responsible for the maturation of the centrosomes, for the activation of the phosphatase Cdc25C, as well as for the activation of the anaphase promoting complex (Glover et al., 1998, Qian, et al., 2001).
  • Plk1 antibodies leads to a G2 arrest in untransformed cells whereas tumour cells arrest in the mitosis phase (Lane and Nigg, 1996).
  • the protein kinase aurora B has been described as having an essential function during entry into mitosis.
  • Aurora B phosphorylates histone H3 at Ser 1 and thereby initiates chromosome condensation (Hsu, J. Y. et al., 2000).
  • a specific cell cycle arrest in the G2/M phase may, however, also be triggered e.g. by the inhibition of specific phosphatases such as e.g. Cdc25C (Russell and Nurse, 1986).
  • Cdc25C e.g. Cdc25C
  • an arrest in the G2/M phase can also be triggered by the inhibition of certain motor proteins, so-capped kinesins such as e.g.
  • the compounds of general formula I according to the invention are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation.
  • Such diseases include, for example: viral infections (e.g. HIV and Kaposi's sarcoma); inflammatory and autoimmune diseases (e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and/or parasitic infections; leukaemias, lymphoma and solid tumours; skin diseases (e.g. psoriasis); bone diseases; cardiovascular diseases (e.g. restenosis and hypertrophy). They are also suitable for protecting proliferating cells (e.g. hair, intestinal, blood and progenitor cells) from damage to their DNA caused by radiation, UV treatment and/or cytostatic treatment (Davis et al., 2001).
  • viral infections e.g. HIV and Kaposi's sarcoma
  • inflammatory and autoimmune diseases e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing
  • bacterial, fungal and/or parasitic infections e.g. colitis, arthritis,
  • the new compounds may be used for the prevention, short-term or long-term treatment of the abovementioned diseases, also in combination with other active substances used for the same indications, e.g. cytostatics.
  • the activity of the compounds according to the invention was determined in the cytotoxicity test on cultivated human tumour cells and/or in a FACS analysis, for example on HeLaS3 cells. In both test methods, the compounds exhibited a good to very good activity, i.e. for example an EC 50 value in the HeLaS3 cytotoxicity test of less than 5 ⁇ mol, generally less than 1 ⁇ mol.
  • HeLaS3 obtained from American Type Culture Collection (ATCC)
  • Ham's F12 Medium Life Technologies
  • 10% foetal calf serum Life Technologies
  • the HeLaS3 cells were placed in 96-well plates (Costar) at a density of 1000 cells per well and incubated overnight in an incubator (at 37° C. and 5% CO 2 ), while on each plate 6 wells were filled only with medium (3 wells as a control of the medium, 3 wells for incubation with reduced AlamarBlue).
  • the active substances were added to the cells in various concentrations (dissolved in DMSO; final concentration: 1%) (in each case as a triple measurement). After 72 hours' incubation, 20 ⁇ l of AlamarBlue (AccuMed International) were added to each well, and the cells were incubated for a further 7 hours. As a control, 20 ⁇ l of reduced Alamar Blue (AlamarBlue reagent which had been autoclaved for 30 min) were added to 3 wells. After 7 h incubation the colour change of the AlamarBlue reagent in the individual wells was determined in a Perkin Elmer fluorescence spectrophotometer (excitation 530 nm, emission 590 nm, slits 15, integrate time 0.1).
  • the amount of AlamarBlue reagent reacted represents the metabolic activity of the cells.
  • the relative cell activity was calculated as a percentage of the control (HeLa S3 cells without inhibitor) and the active substance concentration which inhibits the cell activity by 50% (IC 50 ) was obtained. The values were calculated from the average of three individual measurements, correcting for the control value (medium control).
  • Propidium iodide binds stoichiometrically to double-stranded DNA, and is thus suitable for determining the percentage of cells in the G1, S and G2/M phase of the cell cycle on the basis of the cell DNA content.
  • Cells in the G0 and G1 phase have a diploid DNA content (2N), whereas cells in G2 or mitosis have a 4N DNA content.
  • HeLaS3 cells For PI staining, 0.4 million HeLaS3 cells were seeded, for example, on a 75 cm 2 cell culture flask, and after 24 h either 1% DMSO was added as control or the substance was added in various concentrations (in 1% DMSO). The cells were incubated for 24 h with the substance or with DMSO, before the cells were washed with 2 ⁇ PBS and detached with trypsin/EDTA. The cells were centrifuged (1000 rpm, 5 min, 4° C.), and the cell pellet was washed 2 ⁇ with PBS, before the cells were resuspended in 0.1 ml of PBS. Then the cells were fixed with 80% ethanol for 16 hours at 4° C.
  • the fixed cells (10 6 cells) were centrifuged (1000 rpm, 5 min, 4° C.), washed with PBS and then centrifuged again.
  • the cell pellet was resuspended in 2 ml of Triton X-100 in 0.25% PBS, and incubated for 5 min on ice, before 5 ml of PBS were added and the mixture was centrifuged again.
  • the cell pellet was resuspended in 350 ⁇ l of PI stain solution (0.1 mg/ml of Raze A, 10 ⁇ g/ml of presidium iodide in 1 ⁇ PBS).
  • the cells were incubated for 20 min in the dark with the stain buffer before being transferred into sample measuring vessels for the FACS scan.
  • the DNA measurement was carried out in a Becton Dickinson FACS Analyzer, with an argon laser (500 mW, emission 488 nm), and the DNA Cell Quest Program (BD).
  • the logarithmic PI fluorescence was determined with a band-pass filter (BP 585/42).
  • the cell populations in the individual phases of the cell cycle were quantified with the ModFit LT program of Becton Dickinson.
  • the compounds of general formula (I) may be used on their own or combined with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances.
  • suitable preparations include for example tablets, capsules, suppositories, solutions, particularly solutions for injection (s.c., i.v., i.m.) and infusion, syrups, emulsions or dispersible powders.
  • the amount of pharmaceutically active compound in each case should be in the range from 0.1-90 wt. %, preferably 0.5-50 wt. % of the total composition, i.e. in amounts which are sufficient to achieve the dosage range given below.
  • the doses specified may, if necessary, be given several times a day.
  • Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • excipients for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • excipients for example inert dilu
  • Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core may also consist of a number of layers.
  • the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
  • Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • a sweetener such as saccharin, cyclamate, glycerol or sugar
  • a flavour enhancer e.g. a flavouring such as vanillin or orange extract.
  • suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, while if water is used as the diluent organic solvents may optionally be used as solubilisers or auxiliary solvents, and transferred into injection vials or ampoules or infusion bottles.
  • preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants
  • solubilisers or auxiliary solvents may optionally be used as solubilisers or auxiliary solvents, and transferred into injection vials or ampoules or infusion bottles.
  • Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
  • Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
  • Suitable excipients may be, for example, water, pharmaceutically acceptable organic solvents, such as paraffins (e.g. petroleum fractions), oils of vegetable origin (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolin, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silica and silicates), sugar (e.g. glucose, lactose and dextrose), emulsifiers (e.g.
  • paraffins e.g. petroleum fractions
  • oils of vegetable origin e.g. groundnut or sesame oil
  • mono- or polyfunctional alcohols e.g. ethanol or glycerol
  • carriers such as e.g. natural mineral powders (e.g. kaolin, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silica
  • lignin e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone
  • lubricants e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate.
  • the preparations are administered in the usual way, preferably by oral or transdermal route, particularly preferably by oral route.
  • the tablets may, of course, contain additives, such as e.g. sodium citrate, calcium carbonate and dicalcium phosphate together with various additives, such as starch, preferably potato starch, gelatine and the like, in addition to the abovementioned carriers.
  • Lubricants such as magnesium stearate, sodium laurylsulphate and talc may also be used to form tablets.
  • the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients.
  • solutions of the active substances may be prepared using suitable liquid carrier materials.
  • the dosage for intravenous use is 1-1000 mg per hour, preferably between 5-500 mg per hour.
  • the active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic.
  • the solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
  • the ampoules contain 5 mg, 25 mg and 50 mg of active substance.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are new dihydropteridinones of general formula (I)
Figure US20050014760A1-20050120-C00001
wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

Description

    RELATED APPLICATION DATA
  • This application is a continuation application of U.S. application Ser. No. 10/374,876 filed Feb. 26, 2003.
  • The present invention relates to new dihydropteridinones of general formula (I)
    Figure US20050014760A1-20050120-C00002
    wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
    • BACKGROUND OF THE INVENTION
  • Pteridinone derivatives are known from the prior art as active substances with an antiproliferative activity. WO 01/019825 describes the use of pteridinone derivatives for the treatment of neoplastic and viral diseases. The resistance of many types of tumours calls for the development of new pharmaceutical compositions for combating tumours.
  • The aim of the present invention is to prepare new compounds with antiinflammatory and antiproliferative activity.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Surprisingly it has been found that compounds of general formula (I) wherein the groups L and R1 to R5 have the meanings given hereinafter act as inhibitors of specific cell cycle kinases. Thus, the compounds according to the invention may be used for example to treat diseases connected with the activity of specific cell cycle kinases and characterised by excessive or abnormal cell proliferation.
  • The present invention therefore relates to compounds of general formula (I)
    Figure US20050014760A1-20050120-C00003
    wherein
      • R1, R2 which may be identical or different, denote hydrogen or optionally substituted C1-C6-alkyl, or
      • R1 and R2 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms,
      • R3 denotes hydrogen or a group selected from among optionally substituted C1-C12-alkyl, C2-C12-alkenyl, C2-C12-alkynyl and C6-C14-aryl, or a group selected from among optionally substituted and/or bridged C3-C12-cycloalkyl, C3-C12-cycloalkenyl, C7-C12-polycycloalkyl, C7-C12-polycycloalkenyl, C5-C12-spirocycloalkyl, C3-C12-heterocycloalkyl which contains 1 to 2 heteroatoms, and C3-C12-heterocycloalkenyl which contains 1 to 2 heteroatoms, or
      • R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 heteroatom,
      • R4 denotes a group selected from among hydrogen, —CN, hydroxy, —NR6R7 and halogen, or
      • a group selected from among optionally substituted C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C5-alkyloxy, C2-C5-alkenyloxy, C2-C5-alkynyloxy, C1-C6-alkylthio, C1-C6-alkylsulphoxo and C1-C6-alkylsulphonyl,
      • L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, —C2-C4-alkyl-C6-C14-aryl, —C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms,
      • n denotes 0 or 1
      • m denotes 1 or 2
      • R5 denotes a group selected from among optionally substituted morpholinyl, piperidinyl, piperazinyl, piperazinylcarbonyl, pyrrolidinyl, tropenyl, R8-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, —NR8R9 and azacycloheptyl,
      • R6, R7 which may be identical or different, denote hydrogen or C1-C4-alkyl, and
      • R8, R9 denote unsubstituted nitrogen substituents at R5, which may be identical or different, denote either hydrogen or a group selected from among C1-C6-alkyl, —C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, —C1-C4-alkyl-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl- and C6-C14-aryl-C1-C4-alkylsulphonyl-, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
  • Preferred compounds of formula (I) are those wherein
      • R1 to R4, R6 and R7 are as hereinbefore defined, and
      • L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, —C2-C4-alkyl-C6-C14-aryl, —C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms
      • n denotes 1
      • m denotes 1 or 2
      • R5 denotes a group which is bound to L via a nitrogen atom, selected from among optionally substituted morpholinyl, piperidinyl, R8-piperazinyl, pyrrolidinyl, tropenyl, R8-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, —NR8R9 and azacycloheptyl,
      • R8, R9 denote unsubstituted nitrogen substituents at R5, which may be identical or different, hydrogen or a group selected from among C1-C6-alkyl, —C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, —C1-C4-alkyl-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl,
      • optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
  • Also preferred are compounds of formula (I), wherein
      • R1 to R4, R6 and R7 are as hereinbefore defined,
      • L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, —C2-C4-alkyl-C6-C14-aryl, —C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms
      • n denotes 0 or 1
      • m denotes 1 or 2
      • R5 denotes a group which is bound to L via a carbon atom, selected from among R8-piperidinyl, R8R9-piperazinyl, R8-pyrrolidinyl, R8-piperazinylcarbonyl, R8-tropenyl, R8-morpholinyl and R8-azacycloheptyl, and
      • R8, R9 denote unsubstituted nitrogen substituents at R5, which may be identical or different, hydrogen or a group selected from among C1-C6-alkyl, —C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, —C1-C4-alkyl-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl,
      • optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
  • Particularly preferred are compounds of formula I wherein
      • L, m, n and R3 to R9 are as hereinbefore defined, and
      • R1, R2 which may be identical or different, denote a group selected from among hydrogen, Me, Et, Pr, or
      • R1 and R2 together form a C2-C4-alkyl bridge,
      • optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
  • Especially preferred are compounds of formula I wherein
      • R1 , R2, m, n and R5 to R8 are as hereinbefore defined, and
      • R3 denotes a group selected from among optionally substituted C1-C10-alkyl, C3-C7-cycloalkyl, C3-C6-heterocycloalkyl and C6-C14-aryl or
      • R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 to 2 heteroatoms,
      • R4 denotes a group selected from among hydrogen, OMe, OH, Me, Et, Pr, OEt, NHMe, NH2, F, CL, Br, O-propargyl, O-butynyl, CN, SMe, NMe2, CONH2, ethynyl, propynyl, butynyl and allyl,
      • and
      • L denotes a linker selected from among optionally substituted phenyl, phenylmethyl, cyclohexyl and branched C1-C6-alkyl,
      • optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
  • The invention further relates to compounds of formula I for use as pharmaceutical compositions.
  • Of particular importance according to the invention are compounds of formula I for use as pharmaceutical compositions with an antiproliferative activity.
  • The invention also relates to the use of a compound of formula I for preparing a pharmaceutical composition for the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.
  • The invention also relates to a method of treating and/or preventing cancer, infections, inflammatory and autoimmune diseases, characterised in that a patient is given an effective amount of a compound of formula I.
  • The invention also relates to pharmaceutical preparations, containing as active substance one or more compounds of general formula (I) or the physiologically acceptable salts thereof, optionally combined with conventional excipients and/or carriers.
  • The invention also relates to a process for preparing a compound of general formula (I),
    Figure US20050014760A1-20050120-C00004
    wherein
      • R1-R5, m, n and L are as hereinbefore defined, characterised in that a compound of general formula (II)
        Figure US20050014760A1-20050120-C00005
        wherein
      • R1-R3 are as hereinbefore defined and A is a leaving group, is reacted with an optionally substituted compound of general formula (III),
        Figure US20050014760A1-20050120-C00006
        wherein
      • R4 is as hereinbefore defined and
      • R10 denotes OH, NH-L-R5, —O-methyl, —O-ethyl, and optionally then the product of general formula (IV)
        Figure US20050014760A1-20050120-C00007
        wherein
      • R1 to R4 is as hereinbefore defined and
      • R10 denotes OH, —NH-L-R5, —O-methyl or —O-ethyl,
      • optionally after previous hydrolysis of the ester group —COR10, is reacted with an amine of general formula (V)
        NH2-L-R5 m   (V)
        wherein
      • R5 is as hereinbefore defined.
  • The invention further relates to a compound of formula (II),
    Figure US20050014760A1-20050120-C00008
    wherein
      • R1-R3 are as hereinbefore defined and A is a leaving group.
  • The term alkyl groups, including alkyl groups which are a part of other groups, denotes branched and unbranched alkyl groups with 1 to 12 carbon atoms, preferably 1-6, most preferably 1-4 carbon atoms, such as, for example: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl. Unless otherwise stated, the abovementioned terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl include all the possible isomeric forms. For example, the term propyl includes the two isomeric groups n-propyl and iso-propyl, the term butyl includes n-butyl, iso-butyl, sec. butyl and tert.-butyl, the term pentyl includes iso-pentyl, neopentyl, etc.
  • In the abovementioned alkyl groups one or more hydrogen atoms may optionally be replaced by other groups. For example these alkyl groups may be substituted by fluorine. All the hydrogen atoms of the alkyl group may optionally also be replaced.
  • The term alkyl bridge, unless otherwise stated, denotes branched and unbranched alkyl groups with 1 to 5 carbon atoms, for example methylene, ethylene, propylene, isopropylene, n-butylene, iso-butyl, sec. butyl and tert.-butyl etc. bridges. Methylene, ethylene, propylene and butylene bridges are particularly preferred. In the alkyl bridges mentioned 1 to 2 C-atoms may optionally be replaced by one or more heteroatoms selected from among oxygen, nitrogen or sulphur.
  • The term alkenyl groups (including those which are a part of other groups) denotes branched and unbranched alkylene groups with 2 to 10 carbon atoms, preferably 2-6 carbon atoms, most preferably 2-3 carbon atoms, provided that they have at least one double bond. Examples include: ethenyl, propenyl, butenyl, pentenyl etc. Unless otherwise stated, the abovementioned terms propenyl, butenyl, etc also include all the possible isomeric forms. For example, the term butenyl includes 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl and 1-ethyl-1-ethenyl.
  • In the abovementioned alkenyl groups, unless otherwise stated, one or more hydrogen atoms may optionally be replaced by other groups. For example, these alkyl groups may be substituted by the halogen atom fluorine. All the hydrogen atoms of the alkenyl group may optionally also be replaced.
  • The term alkynyl groups (including those which are a part of other groups) denotes branched and unbranched alkynyl groups with 2 to 10 carbon atoms, provided that they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl etc., preferably ethynyl or propynyl.
  • In the abovementioned alkynyl groups, unless otherwise stated, one or more hydrogen atoms may optionally be replaced by other groups. For example, these alkyl groups may be substituted by fluorine. All the hydrogen atoms of the alkynyl group may optionally also be replaced.
  • The term aryl denotes an aromatic ring system with 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, preferably phenyl, which, unless otherwise stated, may carry one or more of the following substituents, for example: OH, NO2, CN, OMe, —OCHF2, —OCF3, —NH2, halogen, for example fluorine or chlorine, C1-C10-alkyl, preferably C1-C5-alkyl, preferably C1-C3-alkyl, most preferably methyl or ethyl, —O—C1-C3-alkyl, preferably —O-methyl or —O-ethyl, —COOH, —COO—C1-C4-alkyl, preferably —O-methyl or —O-ethyl, —CONH2.
  • Examples of heteroaryl groups wherein up to two carbon atoms are replaced by one or two nitrogen atoms include pyrrole, pyrazole, imidazole, triazole, pyridine, pyrimidine, while each of the abovementioned heteroaryl rings may optionally also be anellated to a benzene ring, preferably benzimidazole, and unless otherwise stated these heterocycles may carry one or more of the following substituents, for example: F, Cl, Br, OH, OMe, methyl, ethyl, CN, CONH2, NH2, optionally substituted phenyl, optionally substituted heteroaryl, preferably optionally substituted pyridyl.
  • Examples of cycloalkyl groups are cycloalkyl groups with 3-12 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl, while each of the abovementioned cycloalkyl groups may optionally also carry one or more substituents, for example: OH, NO2, CN, OMe, —OCHF2, —OCF3, —NH2 or halogen, preferably fluorine or chlorine, C1-C10-alkyl, preferably C1-C5-alkyl, preferably C1-C3-alkyl, more preferably methyl or ethyl, —O—C1-C3-alkyl, preferably —O-methyl or —O-ethyl, —COOH, —COO-C1-C4-alkyl, preferably —COO-methyl or —COO-ethyl or —CONH2. Particularly preferred substituents of the cycloalkyl groups are ═O, OH, NH2, methyl or F.
  • Examples of cycloalkenyl groups are cycloalkyl groups with 3-12 carbon atoms which have at least one double bond, for example cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, preferably cyclopropenyl, cyclopententyl or cyclohexenyl, while each of the abovementioned cycloalkenyl groups may optionally also carry one or more substituents.
  • “═O” denotes an oxygen atom linked via a double bond.
  • Examples of heterocycloalkyl groups, unless otherwise described in the definitions, include 3- to 12-membered, preferably 5-, 6- or 7-membered, saturated or unsaturated heterocycles which may contain as heteroatoms nitrogen, oxygen or sulphur, for example tetrahydrofuran, tetrahydrofuranone, γ-butyrolactone, α-pyran, γ-pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolan, dithiolan, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepan, oxazine, tetrahydro-oxazinyl, isothiazole, pyrazolidine, preferably morpholine, pyrrolidine, piperidine or piperazine, while the heterocyclic group may optionally carry substituents, for example C1-C4-alkyl, preferably methyl, ethyl or propyl.
  • Examples of polycycloalkyl groups are optionally substituted, bi-, tri-, tetra- or pentacyclic cycloalkyl groups, for example pinane, 2,2,2-octane, 2,2,1-heptane or adamantane. Examples of polycycloalkenyl groups are optionally bridged and/or substituted 8-membered bi-, tri-, tetra- or pentacyclic cycloalkenyl groups, preferably bicycloalkenyl or tricycloalkenyl groups, if they have at least one double bond, for example norbornene.
  • Examples of spiroalkyl groups are optionally substituted spirocyclic C5-C12 alkyl groups.
  • Generally, the term halogen denotes fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, most preferably chlorine.
  • The leaving group A denotes either identical or different leaving groups such as for example -o-methyl, —SCN, chlorine, bromine, iodine, methanesulphonyl, trifluoromethanesulphonyl or p-toluenesulphonyl, preferably chlorine.
  • The compounds according to the invention may be present in the form of the individual optical isomers, mixtures of the individual enantiomers, diastereomers or racemates, in the form of the tautomers and also in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids—such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
  • The substituent R1 may denote hydrogen or a group selected from among optionally substituted and/or branched C1-C6-alkyl, preferably methyl or ethyl, more preferably methyl or ethyl.
  • The substituent R2 may denote hydrogen or a group selected from among optionally substituted and/or branched C1-C6-alkyl, preferably methyl or ethyl.
  • R1 and R2 together may denote a 2- to 5-membered alkyl bridge, preferably an ethylene, propylene or butylene bridge which may contain 1 to 2 heteroatoms, preferably oxygen or nitrogen, more preferably ethylene, propylene.
  • The substituent R3 may denote hydrogen or a group selected from among optionally substituted and/or branched C1-C12-alkyl, preferably ethyl, propyl, butyl, pentyl or hexyl, more preferably propyl, butyl, pentyl or hexyl, C2-C12-alkenyl, preferably C5-C7-alkenyl, C2-C12-alkynyl, preferably C5-C7-alkynyl and C6-C14-aryl, preferably phenyl, a group selected from among optionally substituted and/or bridged C3-C12-cycloalkyl, preferably cyclopentyl or cyclohexyl, C3-C12-cycloalkenyl, preferably C5-C7-cycloalkenyl, C7-C12-polycycloalkyl, C7-C12-polycycloalkenyl, C5-C12-spirocycloalkyl, C3-C12-heterocycloalkyl, preferably pyranyl or piperinyl, pyrrolidinyl, pyrazinyl or morpholinyl which contains 1 to 2 heteroatoms, preferably oxygen or nitrogen, and C3-C12-heterocycloalkenyl which contains 1 to 2 heteroatoms, preferably oxygen or nitrogen.
  • Most preferably, the substituent R3 denotes isopropyl, isobutyl, isopentyl, cyclopentyl, phenyl or cyclohexyl.
  • R1 and R3 or R2 and R3 together may denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 heteroatom, preferably oxygen or nitrogen.
  • The substituent R4 may denote a group selected from among hydrogen, —CN, hydroxy, —NR6R7 and Halogen, preferably chlorine or fluorine, more preferably chlorine or a group selected from among optionally substituted C1-C6-alkyl, preferably methyl, ethyl or propyl, C2-C6-alkenyl, preferably ethenyl or propenyl, C2-C6-alkynyl, preferably ethynyl, propynyl or butynyl, C1-C5-alkyloxy, preferably methoxy, ethoxy or propargyloxy, C2-C5-alkenyloxy, C2-C5-alkynyloxy, C1-C6-alkylthio, C1-C6-alkylsulphoxo and C1-C6-alkylsulphonyl.
  • Most preferably, the substituent R4 denotes methoxy, methyl, ethoxy, ethyl, propargyloxy or chlorine.
  • L may denote a linker selected from among optionally substituted C2-C10-alkyl, preferably ethyl, propyl, butyl or pentyl, C2-C10-alkenyl, C6-C14-aryl, preferably phenyl, —C2-C4-alkyl-C6-C14-aryl, —C6-C14-aryl-C1-C4-alkyl, preferably -phenyl-methyl optionally bridged C3-C12-cycloalkyl, preferably cyclohexyl, and heteroaryl which contains 1 or 2 nitrogen atoms.
      • n denotes 0 or 1
      • m denotes 1 or 2, preferably 1.
  • R5 may denote a group selected from among optionally substituted morpholinyl, piperidinyl, piperazinyl, piperazinylcarbonyl, pyrrolidinyl, tropenyl, R8-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, —NR8R9 and azacycloheptyl, preferably piperidinyl, morpholinyl, pyrrolidinyl, sulphoxomorpholiny, piperazinyl, thiomorpholinyl or tropenyl.
  • The groups R6 and R7 may be identical or different and may denote hydrogen or C1-C4-alkyl, preferably methyl or ethyl.
  • The groups R8 and R9 may be unsubstituted nitrogen substituents at R5, they may be identical or different and denote either hydrogen or a group selected from among C1-C6-alkyl, preferably methyl, ethyl or propyl, —C1-C4-alkyl-C3-C10-cycloalkyl, preferably —CH2-cyclopropyl, C3-C10-cycloalkyl, C6-C14-aryl, preferably phenyl, —C1-C4-alkyl-C6-C14-aryl, preferably benzyl, pyranyl, pyridinyl, pyrimidinyl, pyranyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl.
  • Most preferably, the substituent R8 denotes methyl, ethyl or propyl.
  • Most preferably, the substituent R9 denotes methyl, ethyl or propyl.
  • R10 may be a substituent selected from among OH, NH2-LR5, —O-methyl and —O-ethyl, preferably OH, LR5, —O-methyl or —O-ethyl.
  • All the groups mentioned in the definition of R1 to R10 may optionally be branched and/or substituted.
  • The compounds according to the invention may be prepared by synthesis methods A described hereinafter, while the substituents of general formulae (A1) to (A9) have the meanings given hereinbefore. This method is to be understood as an illustration of the invention without restricting it to the subject matter thereof.
  • Method A
  • Step 1A
  • A compound of formula (A1) is reacted with a compound of formula (A2) to obtain a compound of formula (A3) (Diagram 1A). This reaction may be carried out according to WO 0043369 or WO 0043372. Compound (A1) is commercially obtainable, for example, from City Chemical LLC, 139 Allings Crossing Road, West Haven, Conn., 06516, USA. Compound (A2) may be prepared by procedures known from the literature: (a) F. Effenberger, U. Burkhart, J. Willfahrt Liebigs Ann. Chem. 1986, 314-333; b) T. Fukuyama, C.-K. Jow, M. Cheung, Tetrahedron Lett. 1995, 36, 6373-6374; c) R. K. Olsen, J. Org. Chem. 1970, 35, 1912-1915; d) F. E. Dutton, B. H. Byung Tetrahedron Lett. 1998, 30, 5313-5316; e) J. M. Ranajuhi, M. M. Joullie Synth. Commun. 1996, 26, 1379-1384.).
    Diagram 1A
    Figure US20050014760A1-20050120-C00009
  • In Step 1A, 1 equivalent of the compound (A1) and 1 to 1.5 equivalents, preferably 1.1 equivalents of a base, preferably potassium carbonate, potassium hydrogen carbonate, sodium carbonate or sodium hydrogen carbonate, calcium carbonate, most preferably potassium carbonate, are stirred in a diluent optionally mixed with water, for example acetone, tetrahydrofuran, diethylether, cyclohexane, petroleum ether or dioxane, preferably cyclohexane or diethylether.
  • At a temperature of 0 to 15° C., preferably 5 to 10° C., 1 equivalent of an amino acid of formula (A2), dissolved in an organic solvent, for example acetone, tetrahydrofuran, diethylether, cyclohexane or dioxane, is added dropwise. The reaction mixture is heated to a temperature of 18° C. to 30° C., preferably about 22° C., with stirring and then stirred for a further 10 to 24 hours, preferably about 12 hours. Then the diluent is distilled off, the residue is combined with water and the mixture is extracted two to three times with an organic solvent, such as diethylether or ethyl acetate, preferably ethyl acetate. The combined organic extracts are dried and the solvent is distilled off. The residue (compound A3) may be used in Step 2 without any prior purification.
  • Step 2A
  • The compound obtained in Step 1A (A3) is reduced at the nitro group and cyclised to form the compound of formula (A4) (Diagram 2A).
    Diagram 2A
    Figure US20050014760A1-20050120-C00010
    [Reduktion=Reduction]
  • In Step 2A, 1 equivalent of the nitro compound (A3) is dissolved in an acid, preferably glacial acetic acid, formic acid or hydrochloric acid, preferably glacial acetic acid, and heated to 50 to 70° C. preferably about 60° C. Then a reducing agent, for example zinc, tin or iron, preferably iron filings, is added to complete the exothermic reaction and the mixture is stirred for 0.2 to 2 hours, preferably 0.5 hours, at 100 to 125° C., preferably at about 117° C. After cooling to ambient temperature the iron salt is filtered off and the solvent is distilled off. The residue is taken up in a solvent or mixture of solvents, for example ethyl acetate or dichloromethane/methanol 9/1 and semisaturated NaCl solution, and filtered through kieselgur, for example. The organic phase is dried and evaporated down. The residue (compound (A4)) may be purified by chromatography or by crystallisation or used as the crude product in Step 3A of the synthesis.
  • Step 3A
  • The compound obtained in Step 2A (A4) may be reacted by electrophilic substitution as shown in Diagram 3A to obtain the compound of formula (A5).
    Diagram 3A
    Figure US20050014760A1-20050120-C00011
  • In Step 3A 1 equivalent of the amide of formula (A4) is dissolved in an organic solvent, for example dimethylformamide or dimethylacetamide, preferably dimethylacetamide, and cooled to about −5 to 5° C., preferably 0° C. Then 0.9 to 1.3 equivalents of sodium hydride and 0.9 to 1.3 equivalents of a methylating reagent, e.g. methyl iodide, are added. The reaction mixture is stirred for 0.1-3 hours, preferably about 1 hour, at about 0 to 10° C., preferably at about 5° C., and may optionally be left to stand for a further 12 hours at this temperature. The reaction mixture is poured onto ice water and the precipitate is isolated. The residue (compound (A5)) may be purified by chromatography, preferably over silica gel, or by crystallisation, or used as the crude product in step 4A of the synthesis.
  • Step 4A
  • The amination of the compound (A5) obtained in Step 3A to yield the compound of formula (A9) (Diagram 4A) may be carried out using the methods known from the literature of variants 4.1 A (a) M. P. V. Boarland, J. F. W. McOmie J. Chem. Soc. 5 1951, 1218-1221; b) F. H. S. Curd, F. C. Rose J. Chem. Soc. 1946, 343-348., 4.2 A (a) Banks J. Am. Chem. Soc. 1944, 66, 1131 b) Ghosh and Dolly J. Indian Chem. Soc. 1981, 58, 512-513; c) N. P. Reddy and M. Tanaka Tetrahedron Lett. 1997, 38, 4807-4810.
    Diagram 4A
    Figure US20050014760A1-20050120-C00012
  • For example, in variant 4.1 A, 1 equivalent of the compound (A5) and 1 to 3 equivalents, preferably about 2 equivalents of the compound (A6) are heated without a solvent or in an organic solvent such as for example sulpholane, dimethylformamide, dimethylacetamide, toluene, N-methylpyrrolidone, dimethylsulphoxide or dioxane, preferably sulpholane, for 0.1 to 4 hours, preferably 1 hour, at 100 to 220° C., preferably at about 160° C. After cooling, the product (A9) is crystallised by the addition of organic solvents or mixtures of solvents, e.g. diethylether/methanol, ethyl acetate, methylene chloride, or diethylether, preferably diethylether/methanol 9/1, or purified by chromatography.
  • For example, in variant 4.2 A, 1 equivalent of the compound (A5) and 1 to 3 equivalents of the compound (A6) are stirred with acid, for example 1-10 equivalents of 10-38% hydrochloric acid and/or an alcohol, for example ethanol, propanol, butanol, preferably ethanol, at reflux temperature for 1 to 48 hours, preferably about 5 hours.
  • The product precipitated (A9) is filtered off and optionally washed with water, dried and crystallised from a suitable organic solvent.
  • For example, in variant 4.3 A, 1 equivalent of the compound (A5) and 1 to 3 equivalents of the compound (A7) are dissolved in a solvent, for example toluene or dioxane and combined with a phosphine ligand, for example 2,2′-bis-(diphenylphosphino)-1,1′-binaphthyl and a palladium catalyst, for example tris(dibenzylidene-acetone)-dipalladium(0) and a base, for example caesium carbonate, and refluxed for 1-24 h, preferably 17 h. The reaction mixture is purified for example over silica gel and the product (A8) is isolated from the solution or obtained by suitable crystallisation.
  • The product (A8) is dissolved in a suitable solvent, for example dioxane and mixed with acid, for example semiconcentrated hydrochloric acid, for example in the ratio of solvent to acid of 3:1. Then the mixture is refluxed for 1-48 h, for example 12 h, and the precipitate formed is isolated. If desired the product (A9) is purified by crystallisation.
  • Step 5A
  • Diagram 5A
    Figure US20050014760A1-20050120-C00013
    Variant 5.1 A:
  • For example, 1 equivalent of the compound (A9) is dissolved with 1 equivalent of an activating reagent, e.g. O-benzotriazolyl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) and a base, for example 1.5 equivalents of diisopropylethylamine (DIPEA) in an organic diluent, for example dichloromethane, tetrahydrofuran, dimethylformamide, N-methylpyrrolidone, dimethylacetamide, preferably dichloromethane or dimethylformamide. After the addition of 1 equivalent of the amine (A10) the reaction mixture is stirred for 0.1 to 24 hours, preferably about 2 hours at 20° C. to 100° C. The product of formula (A11) is obtained for example by crystallisation or chromatographic purification.
  • The new compounds of general formula (I) may be synthesised analogously to the following examples of synthesis. These Examples are, however, intended only as examples of procedures to illustrate the invention further, without restricting the invention to their subject matter.
  • The preparation of some intermediate compounds used to synthesise the examples is also described hereinafter.
  • Preparation of the Acids
  • To synthesise the compounds of Examples 94 and 95 first an intermediate
    Figure US20050014760A1-20050120-C00014
    compound Z1
    is prepared as described hereinafter.
  • 50.0 g (0.48 mol) of D-alanine methyl ester×HCl and 49.1 g (0.50 mol) cyclohexanone were placed in 300 mL dichloromethane and then combined with 41.0 g (0.50 mol) sodium acetate and 159.0 g (0.75 mol) sodium triacetoxyborohydride. the mixture was stirred overnight and then 300 mL of 10% sodium hydrogen carbonate solution were added. The aqueous phase was extracted with dichloromethane. The combined organic phases were washed with 10% sodium hydrogen carbonate solution, dried over Na2SO4 and evaporated down.
  • Yield: 72.5 g of a compound Z1a (clear liquid)
  • 72.5 g of the compound Z1a were placed in 500 mL water and 76.6 g (0.39 mol) of 2,4-dichloro-5-nitropyrimidine in 500 mL diethyl ether were added. At a temperature of −5° C. 100 mL 10% potassium hydrogen carbonate solution were added dropwise. The mixture was stirred for 3 h at −5° C. and for a further 12 h at ambient temperature. The organic phase was separated off and dried over Na2SO4. On evaporation the product crystallised out.
  • Yield: 48.0 g of a compound Z1 b (yellow crystals)
  • 48.0 g of the compound Z1 b were dissolved in 350 mL glacial acetic acid and heated to 60° C. 47.5 g of iron powder were added, while the temperature rose to 105° C. The reaction mixture was stirred for three hours at 80° C., then filtered hot through cellulose and evaporated down. The residue was stirred in water and ethyl acetate, suction filtered and the light-grey precipitate was washed with ethyl acetate. The filtrate was washed with dilute ammonia and water, the organic phase was dried over Na2SO4, filtered through activated charcoal and evaporated down. Some more light-grey solid was obtained.
  • Yield: 29.5 g of a compound Z1c (light-grey crystals)
  • 32.1 g of the compound Z1c were placed in 300 mL dimethylacetamide and combined with 13 mL (0.2 mol) methyl iodide. At −5° C. 6.4 g (0.16 mol) sodium hydride as a 60% dispersion in mineral oil was added batchwise. After 2 h the reaction mixture was poured onto 800 mL ice water. The precipitate formed was suction filtered and washed with petroleum ether.
  • Yield: 33.0 g of a compound Z1d (beige crystals)
  • 4.0 g of the compound Z1d and 2.3 g (15 mmol) 4-amino-3-methylbenzoic acid were suspended in 50 mL ethanol and 120 mL water, combined with 2 mL conc. hydrochloric acid and refluxed for 48 h. The precipitate formed on cooling was suction filtered and washed with water, ethanol and diethyl ether.
  • Yield: 2.9 g of a compound Z1 (colourless crystals)
  • To synthesise the compounds Example 188 and Example 203 first of all an intermediate compound Z2
    Figure US20050014760A1-20050120-C00015
    is prepared as described below.
  • A solution of 128.2 g (0.83 mol) D-alanine ethyl ester×HCl and 71.5 g (0.85 mol) cyclopentanone in 1500 mL dichloromethane was combined with 70.1 (0.85 mol) sodium acetate and 265.6 g (1.25 mol) sodium triacetoxyborohydride. The reaction mixture was stirred for 12 h and then poured into 1.5 L of a 10% sodium hydrogen carbonate solution. The aqueous phase was extracted with dichloromethane. The combined organic phases were dried over Na2SO4 and evaporated down.
  • Yield: 143.4 g of a compound Z2a (colourless oil)
  • 66.0 g of the compound Z2a were placed in 500 mL water and combined with 85.0 g (0.44 mol) 2,4-dichloro-5-nitropyrimidine in 500 mL diethyl ether. At −5° C. 100 mL 10% potassium hydrogen carbonate solution were added dropwise and the reaction mixture was stirred for 48 h at ambient temperature. The aqueous phase was extracted with diethyl ether, the combined organic phases were dried over Na2SO4 and evaporated down. The dark red solid was stirred with petroleum ether and suction filtered.
  • Yield: 88.0 g of a compound Z2b (yellow crystals)
  • 88.0 g of the compound Z2b were dissolved in 1000 mL glacial acetic acid and at 60° C. combined batchwise with 85 g iron powder, while the temperature rose to 110° C. It was stirred for 1 h at 60° C., then suction filtered hot through cellulose and evaporated down. The brown solid was stirred with 700 mL water and suction filtered.
  • Yield: 53.3 g of a compound Z2c (light brown crystals)
  • 53.3 g of the compound Z2c were dissolved in 300 mL dimethylacetamide and combined with 13 mL (0.21 mol) methyl iodide. At −5° C. 5.0 g (0.21 mol) sodium hydride as a 60% dispersion in mineral oil were added batchwise. After 12 h the reaction mixture was poured onto 1000 mL ice water and the precipitate formed was suction filtered.
  • Yield: 40.0 g of a compound Z2d (colourless crystals)
  • 4.0 g of the compound Z2d and 2.8 g (16 mmol) 4-amino-3-chlorbenzoic acid were suspended in 25 mL ethanol and 60 mL water, combined with 3 mL conc. hydrochloric acid and refluxed for 43 h. The precipitate formed on cooling was suction filtered and washed with water, ethanol and diethyl ether.
  • Yield: 0.9 g of a compound Z2 (colourless crystals)
  • To synthesise the compounds of Examples 19, 21, 22, 23, 45, 55, 58, 116, 128, 131, 133, 134, 136, 138, 177, 217, 231, 239, 46, 184, 166 and 187 first of all an intermediate compound Z3
    Figure US20050014760A1-20050120-C00016
    is prepared as described below.
  • 54.0 g (0.52 mol) D-2-aminobutyric acid were suspended in 540 mL methanol and slowly combined with 132 g (1.1 mol) thionyl chloride while cooling with ice. The mixture was refluxed for 1.5 h and then evaporated down. The oil remaining was combined with 540 mL tert-butylmethylether and the colourless crystals formed were suction filtered.
  • Yield: 78.8 g of a compound Z3a (colourless crystals)
  • 74.2 g of the compound Z3a and 43.5 mL (0.49 mol) cyclopentanone were dissolved in 800 mL dichloromethane. After the addition of 40.0 g (0.49 mol) sodium acetate and 150.0 g (0.71 mol) sodium triacetoxyborohydride at 0° C. the mixture was stirred for 12 h at ambient temperature and then 500 mL of 20% sodium hydrogen carbonate solution were added. The aqueous phase was extracted with dichloromethane. The combined organic phases were washed with water, dried over MgSO4 and evaporated down.
  • Yield: 85.8 g of a compound Z3b (light yellow oil)
  • 40.0 g of the compound Z3b and 30.0 g (0.22 mol) potassium carbonate were suspended in 600 mL acetone and combined with 45.0 g (0.23 mol) 2,4-dichloro-5-nitropyrimidin in 200 mL acetone while cooling with ice. After 12 h a further 5.0 g 2,4-dichloro-5-nitropyrimidin were added and stirred for 3 h. The reaction mixture was evaporated down, taken up in 800 mL ethyl acetate and 600 mL water and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with water, dried over MgSO4 and evaporated down.
  • Yield: 75.0 g of a compound Z3c (brown oil)
  • 100 g of the compound Z3c were dissolved in 650 mL glacial acetic acid and at 70° C. 20 g of iron powder were added batchwise. The mixture was stirred for 1 h at 70° C., then for 1.5 h at 100° C. and then filtered hot through kieselgur. The reaction mixture was evaporated down, taken up in methanol/dichloromethane, applied to silica gel and purified with ethyl acetate by Soxhlet extraction. The solvent was removed and the residue stirred with methanol.
  • Yield: 30.0 g of a compound Z3d (light brown crystals)
  • 25.0 g of the compound Z3d and 6.5 mL (0.1 mol) methyl iodide were placed in 250 mL dimethylacetamide and at −10° C. 3.8 g (0.95 mol) sodium hydride as a 60% dispersion in mineral oil was added. It was stirred for 20 min at 0° C., then for 30 min at ambient temperature and finally ice was added. The reaction mixture was evaporated down and combined with 300 mL water. The precipitate formed was suction filtered and washed with petroleum ether.
  • Yield: 23.0 g of a compound Z3e (colourless solid)
  • 6.0 g of the compound Z3e and 5.1 g (31 mmol) 4-amino-3-methoxybenzoic acid were suspended in 90 mL ethanol and 350 mL water, combined with 3.5 mL conc. hydrochloric acid and refluxed for 48 h. The reaction mixture was evaporated down, the residue stirred with methanol/diethyl ether and the precipitate formed was suction filtered.
  • Yield: 6.3 g of a compound Z3 (light beige crystals)
  • To synthesise the compound of Examples 81, 82, 93, 137 first of all an intermediate compound Z4
    Figure US20050014760A1-20050120-C00017
    is prepared as described below.
  • 25.0 g (0.19 mol) of ethyl 1-aminocyclopropane-1-carboxylate×HCl and 16.8 g (0.20 mol) of cyclopentanone were dissolved in 300 mL of dichloromethane and combined with 16.4 g (0.20 mol) of sodium acetate and 61.7 g (0.29 mol) of sodium triacetoxyborohydride. It was stirred overnight and the reaction mixture was then poured onto 400 mL of 10% sodium hydrogen carbonate solution. The aqueous phase was extracted with dichloromethane. The combined organic phases were dried over Na2SO4 and evaporated down.
  • Yield: 34.5 g of a compound Z4a (colourless oil)
  • 42.5 g (0.22 mol) of 2,4-dichloro-5-nitropyrimidine in 350 mL of diethyl ether were added to a mixture of 34.5 g of the compound Z4a in 350 mL water. At −5° C. the mixture was combined with 80 mL 10% potassium hydrogen carbonate solution and stirred overnight at ambient temperature. The aqueous phase was extracted with diethyl ether. The combined organic phases were dried over Na2SO4 and evaporated down.
  • Yield: 53.8 g of a compound Z4b (brown oil)
  • 20.1 g of the compound Z4b were dissolved in 200 mL glacial acetic acid and combined batchwise at 60° C. with 19.1 g iron powder, during which time the temperature rose to 100° C. The mixture was stirred for 3 h at 60° C., then suction filtered through cellulose and evaporated down. The residue was stirred in water and ethyl acetate and the yellow precipitate was suction filtered. The filtrate was washed with dilute ammonia and water, the organic phase dried over Na2SO4 and evaporated down. After the addition of diethyl ether additional product crystallised out.
  • Yield: 4.0 g of a compound Z4c (yellow crystals)
  • 7.8 9 of the compound Z4c and 2.6 mL (0.04 mol) methyl iodide were dissolved in 100 mL dimethylacetamide and at −5° C. 1.5 g (0.04 mol) sodium hydride were added batchwise as a 60% dispersion in mineral oil. After 2 h the reaction mixture was poured onto ice water and the precipitate formed was suction filtered.
  • Yield: 7.5 g of a compound Z4d (light brown crystals)
  • 3.0 g of the compound Z4d and 1.9 g (11 mmol) 4-amino-3-methoxybenzoic acid were suspended in 40 mL ethanol and 80 mL water, combined with 2 mL conc. hydrochloric acid and refluxed for 20 h. A further 0.5 g of 4-amino-3-methoxybenzoic acid were added and refluxed for48 h. The precipitate formed on cooling was suction filtered and washed with water, ethanol and diethyl ether.
  • Yield: 2.1 g of a compound Z4 (colourless crystals) m.p.: 222-223° C.
  • To synthesise the compounds of Examples 162, 43, 53, 161, 202, 211, 215 and 212 first of all an intermediate compound Z5
    Figure US20050014760A1-20050120-C00018
    is prepared as described below.
  • A mixture of 73.4 mL (0.5 mol) ethyl 2-bromoisobutyrate, 87.1 mL (0.75 mol) of 3-methyl-1-butylamine, 82.5 g (0.6 mol) sodium iodide and 76.0 g (0.6 mol) of potassium carbonate in 1000 mL ethyl acetate was refluxed for3 days. Any salts present were filtered off and the filtrate evaporated down.
  • Yield: 97.0 g of a compound Z5a (red oil)
  • 49.0 g (0.25 mol) of 2,4-dichloro-5-nitropyrimidine and 38.3 g (0.28 mol) of potassium carbonate were suspended in 500 mL acetone and at 0° C. combined with 93.0 g of the compound Z5a in 375 mL acetone. The reaction mixture was stirred overnight at ambient temperature, filtered and evaporated down. The residue dissolved in ethyl acetate was washed with water and the organic phase dried over MgSO4 and evaporated down.
  • Yield: 102.7 g of a compound Z5b (brown oil)
  • 22.7 g of the compound Z5b were dissolved in 350 mL glacial acetic acid and at 60° C. combined batchwise with 17.4 g iron powder. After the addition had ended the mixture was refluxed for 0.5 h, filtered hot and evaporated down. The residue was taken up in 200 mL dichloromethane/methanol (9:1) and washed with sodium chloride solution. The organic phase was suction filtered through kieselguhr, dried over MgSO4, evaporated down and purified by column chromatography (eluant: ethyl acetate/cyclohexane 1:1).
  • Yield: 1.9 g of a compound Z5c (colourless crystals)
  • 1.9 g of the compound Z5c were dissolved in 32 mL dimethylacetamide and while cooling with ice combined with 0.3 g (7 mmol) sodium hydride as a 60% dispersion in mineral oil. After 10 min 0.5 mL (7 mmol) methyl iodide were added and stirred for 3 h at ambient temperature. The reaction mixture was evaporated down and combined with water. The precipitate formed was suction filtered and washed with petroleum ether.
  • Yield: 1.6 g of a compound Z5d (colourless crystals)
  • 14.0 g of the compound Z5d and 10.0 g (0.06 mol) 4-amino-3-methoxybenzoic acid were suspended in 200 mL dioxane and 80 mL water, combined with 10 mL conc. hydrochloric acid and refluxed for 40 h. The precipitate formed on cooling was suction filtered and washed with water, dioxane and diethyl ether.
  • Yield: 13.9 g of a compound Z5 (colourless crystals)
  • To synthesise the compounds of Examples 88, 194, 229 and 89 first of all an intermediate compound Z6
    Figure US20050014760A1-20050120-C00019
    is prepared as described below.
  • 6.0 g (0.06 mol) L-2-aminobutyric acid was placed in 80 mL 0.5 M sulphuric acid and at 0° C. combined with 5.5 g (0.08 mol) sodium nitrite in 15 mL water. The reaction mixture was stirred for 22 h at 0° C., combined with ammonium sulphate and filtered. The filtrate was extracted with diethyl ether and the combined organic dried over MgSO4 and evaporated down.
  • Yield: 6.0 g of a compound Z6a (yellow oil)
  • 200 mL methanol were combined successively with 65.0 mL (0.89 mol) thionyl chloride and 76.0 g of the compound Z6a in 50 mL methanol while cooling with ice. The resulting mixture was stirred for 1 h at 0° C. and 2 h at ambient temperature and then the methanol and remaining thionyl chloride were eliminated in vacuo at 0° C.
  • Yield: 40.0 g of a compound Z6b (yellow oil)
  • 30.0 mL (0.17 mol) of trifluoromethanesulphonic acid anhydride were placed in 150 mL dichloromethane and while cooling with ice a solution of 20.0 g of the compound Z6b and 14.0 mL (0.17 mol) pyridine in 50 mL dichloromethane was added within one hour. The mixture was stirred for 2 h at ambient temperature, any salts formed were suction filtered and then washed with 100 mL water. The organic phase was dried over MgSO4 and evaporated down.
  • Yield: 42.0 g of a compound Z6c (light yellow oil)
  • 42.0 g of the compound Z6c in 200 mL dichloromethane was added dropwise within one hour to a solution of 15.5 mL (0.17 mol) of aniline and 24.0 mL (0.17 mol) of triethylamine in 400 mL dichloromethane while cooling with ice. The mixture was stirred for 1 h at ambient temperature and a further 2 h at 35° C. The reaction mixture was washed with water, dried over MgSO4 and evaporated down. The residue remaining was purified by distillation (95-100° C., 1*10−3 mbar).
  • Yield: 14.0 of a compound Z6d (colourless oil)
  • 14.0 g of the compound Z6d and 16.0 g (0.1 mol) potassium carbonate were suspended in 100 mL acetone and at 10° C. combined with 16.0 g (0.08 mol) of 2,4-dichloro-5-nitropyrimidine. The mixture was stirred for 4 h at 40° C., any salts formed were suction filtered and the filtrate evaporated down. The residue was taken up in 300 mL ethyl acetate and washed with water. The organic phase was dried over MgSO4 and evaporated down.
  • Yield: 31.0 g of a compound Z6e (brown oil)
  • 31.0 g of the compound Z6e were dissolved in 200 mL glacial acetic acid and at 60° C. combined batchwise with 10 g iron powder, during which time the temperature rose to 85° C. The mixture was stirred for a further hour at 60° C., filtered through kieselguhr and evaporated down. The residue was stirred with methanol.
  • Yield: 4.5 g of a compound Z6f (brown crystals)
  • At −20° C. 0.6 g (16 mmol) of sodium hydride as a 60% dispersion in mineral oil were added batchwise to a mixture of 4.5 g of the compound Z6f and 1.0 mL (16 mmol) methyl iodide in 100 mL dimethylacetamide. After 1 h the reaction mixture was combined with 50 mL water and evaporated down. The residue was stirred with 200 mL water, the precipitate is suction filtered and washed with petroleum ether.
  • Yield: 4.5 g of a compound Z6g (colourless crystals)
  • A suspension of 1.5 g of the compound Z6g and 1.4 g (8 mmol) of methyl 4-amino-3-methoxybenzoate in 30 mL toluene was combined with 0.4 g (0.6 mmol) of 2,2′-bis-(diphenylphosphino)-1,1′-binaphthyl, 0.23 g (0.3 mmol) of tris(dibenzylideneacetone)-dipalladium(0) and 7.0 g (21 mmol) of caesium carbonate and refluxed for 17 h. The reaction mixture was applied to silica gel and purified by column chromatography (eluant: dichloromethane/methanol 9:1).
  • Yield: 1.7 g of a compound Z6h (yellow crystals)
  • 1.7 g of the compound Z6h were dissolved in 50 mL dioxane, combined with 15 mL of semiconc. hydrochloric acid and refluxed for 12 h. After cooling the precipitate formed was suction filtered.
  • Yield: 1.1 g of a compound Z6 (colourless solid)
  • To synthesise the compound of Examples 26, 20, 32, 56, 101, 112, 209 first of all an intermediate compound Z7
    is prepared as described below.
    Figure US20050014760A1-20050120-C00020
  • 50.0 g (0.36 mol) D-alanine methyl ester x HCl was suspended in 500 mL of dichloromethane and 35 mL of acetone and combined with 30.0 g (0.37 mol) of sodium acetate and 80.0 g (0.38 mol) of sodium triacetoxyborohydride. The mixture was stirred for 12 h and then poured onto 400 mL of 10% sodium hydrogen carbonate solution. The organic phase was dried over Na2SO4 and evaporated down.
  • Yield: 51.0 g of a compound Z7a (yellow oil)
  • A suspension of 51.0 g of the compound Z7a in 450 mL water was combined with 80.0 g (0.41 mol) of 2,4-dichloro-5-nitropyridine in 450 mL of diethyl ether. At −5° C. 100 mL of 10% potassium hydrogen carbonate solution were added dropwise. The reaction mixture was stirred for 3 h, the organic phase dried over Na2SO4 and evaporated down.
  • Yield: 74 g of a compound Z7b (yellow oil)
  • 18.6 g of the compound Z7b were dissolved in 200 mL glacial acetic acid and at 60° C. combined batchwise with 20.0 g iron powder. The mixture was stirred for 2 h at 60° C. and then suction filtered through cellulose. The residue was dissolved in ethyl acetate and washed with water and conc. ammonia. The organic phase was dried over Na2SO4 and evaporated down. The residue was crystallised from diethyl ether.
  • Yield: 9.8 g of a compound Z7c (colourless crystals)
  • 17.0 g of the compound Z7c and 7 mL (0.1 mol) methyl iodide were dissolved in 200 mL dimethylacetamide and at −5° C. combined with 4.0 g (0.1 mol) of sodium hydride as a 60% dispersion in mineral oil. The reaction mixture was stirred for 30 min and then poured onto 300 mL ice water. The precipitate formed was suction filtered and stirred with petroleum ether.
  • Yield: 14.8 g of a compound Z7d (beige crystals)
  • 0.9 g of the compound Z7d and 1.5 g (9 mmol) 4-amino-3-methoxybenzoic acid were heated to 210° C. for 30 min. After cooling the residue was stirred with ethyl acetate and the precipitate obtained was suction filtered.
  • Yield: 1.2 g of a compound Z7 (grey crystals)
  • The following acids were prepared, for example, analogously to the methods of synthesis described:
    Figure US20050014760A1-20050120-C00021
    • Synthesis of the amino components L-R5
  • The following amines were obtained as follows:
  • 1,1-dimethyl-2-dimethylamino-1-yl-ethylamine and 1,1-dimethyl-2-piperidin-1-yl-ethylamine
    Figure US20050014760A1-20050120-C00022
  • The compounds were prepared according to the following references: a) S. Schuetz et al. Arzneimittel-Forschung 1971, 21, 739-763 b) V. M. Belikov et al. Tetrahedron 1970, 26, 1199-1216. c) E. B. Butler and McMillan J. Amer. Chem. Soc. 1950, 72, 2978.
  • Other amines were prepared as follows, in a modified manner compared with the literature described above.
    • 1,1-dimethyl-2-morpholin-1-yl-ethylamine
  • Figure US20050014760A1-20050120-C00023
  • 8.7 mL morpholine and 9.3 mL 2-nitropropane were prepared, while cooling with ice, 7.5 mL formaldehyde (37%) and 4 mL of a 0.5 mol/L NaOH solution were slowly added dropwise (<10° C.). Then the mixture was stirred for 1 h at 25° C. and 1 h at 50° C. The solution was treated with water and ether and the aqueous phase was extracted 3× with ether. The combined org. phase was dried over NaSO4 and combined with HCl in dioxane (4 mol/l), the precipitate formed was suction filtered.
  • Yield: 21.7 of white powder
  • 5 g of the white powder were dissolved in 80 mL methanol and with the addition of 2 g RaNi treated with hydrogen at 35° C. and 50 psi for 40 minutes. This yielded 3.6 g of 1,1-dimethyl-2-morpholin-1-yl-ethylamine.
  • The following amines were prepared by this method:
    • 1,1-dimethyl-N-methylpiperazin-1-yl-ethylamine
  • Figure US20050014760A1-20050120-C00024
    • 1,1-dimethyl-2-pyrrolidin-1-yl-ethylamine
  • Figure US20050014760A1-20050120-C00025
    • Synthesis of 1,3-dimorpholin-2-amino-propane
  • Figure US20050014760A1-20050120-C00026
  • 5 g of 1,3 Dimorpholine-2-nitropropane obtained from Messrs. Aldrich was dissolved in 80 mL methanol and treated with hydrogen for 5.5 h at 30° C. and 50 psi with the addition of 2 g RaNi. This yielded 4.2 g of 1,3 dimorpholin-2-amino-propane.
    • 4-Aminobenzylmorpholine
  • Figure US20050014760A1-20050120-C00027
  • The preparation of this amine is described in the following reference: S. Mitsuru et al. J. Med. Chem. 2000, 43, 2049-2063
    • 4-amino-1-tetrahydro-4H-pyran-4-yl-piperidine
  • Figure US20050014760A1-20050120-C00028
  • 20 g (100 mmol) of 4-tert-butyloxycarbony-aminopiperidine were dissolved in 250 mL CH2Cl2 and stirred for 12 h at RT with 10 g (100 mmol) tetrahydro-4H-pyran-4-one and 42 g (200 mmol) NaBH(OAc)3. Then water and potassium carbonate were added, the org. phase was separated off, dried and the solvent was eliminated in vacuo. The residue was dissolved in 200 mL CH2Cl2 and stirred for 12 h at RT with 100 mL trifluoroacetic acid. The solvent was eliminated in vacuo, the residue taken up with CHCl3 and evaporated down again, then taken up in acetone and the hydrochloride was precipitated with ethereal HCl. Yield: 14.3 g (56%).
    • cis- and trans-4-morpholino-cyclohexylamine
  • Figure US20050014760A1-20050120-C00029
    • Dibenzyl-4-morpholino-cyclohexylamine
  • 3.9 g (30 mmol) of 4-dibenzylcyclohexanone were dissolved in 100 mL of CH2Cl2 and stirred for 12 h at RT with 3.9 g (45 mmol) of morpholine and 9.5 g (45 mmol) NaBH(OAc)3. Then water and potassium carbonate were added, the org. phase was separated off, dried and the solvent was eliminated in vacuo. The residue was purified through a silica gel column (about 20 mL silica gel; about 500 mL of ethyl acetate 90/methanol 10+1% conc. ammonia). The appropriate fractions were evaporated down in vacuo. Yield: 6.6 g (60%) of cis-isomer and 2 g (18%) of trans-isomer.
  • Alternatively the trans-dibenzyl-4-morpholino-cyclohexylamine may be prepared by the following method:
  • 33 g (112 mmol) of 4-dibenzylcyclohexanone were dissolved in 300 mL MeOH, combined with 17.4 g (250 mmol) of hydroxylamine hydrochloride and stirred for 4 h at 60° C. The solvent was evaporated down in vacuo, combined with 500 mL water and 50 g potassium carbonate and extracted twice with 300 mL of dichloromethane. The org. phase was dried, evaporated down in vacuo, the residue was crystallised from petroleum ether, dissolved in 1.5 L of EtOH and heated to 70° C. 166 g of sodium were added batchwise and the mixture was refluxed until the sodium dissolved. The solvent is eliminated in vacuo, the residue combined with 100 mL water and extracted twice with 400 mL of ether. The org. phase is washed with water, dried, evaporated down in vacuo and the trans isomer is isolated using a column (about 1.5 L silica gel; about 2 L of ethyl acetate 80/methanol 20+2% conc. ammonia). Yield: 12.6 g (41.2%).
  • 6.8 g (23 mmol) of trans-1-amino-4-dibenzylaminocyclohexane was dissolved in 90 mL of DMF and stirred for 8 h at 100° C. with 5 mL (42 mmol) of 2,2′-dichloroethyl ether and 5 g of potassium carbonate. After cooling 30 mL of water was added, the precipitated crystals were suction filtered and purified through a short column (about 20 mL silica gel, about 100 mL ethyl acetate). The residue is crystallised from methanol and conc. HCl as the dihydrochloride. Yield: 7.3 g (72.4%).
    • trans-4-morpholino-cyclohexylamine
  • 7.2 g (16.4 mmol) of trans-dibenzyl-4-morpholino-cyclohexylamine were dissolved in 100 mL of MeOH and hydrogenated on 1.4 g of Pd/C (10%) at 30-50° C. The solvent was eliminated in vacuo and the residue was crystallised from ethanol and conc. HCl. Yield: 3.9 g (93%); m.p. 312° C.
  • The cis isomer can be prepared analogously.
    • cis- and trans-4-piperidino-cyclohexylamine
  • Figure US20050014760A1-20050120-C00030
    • trans-dibenzyl-4-piperidino-cyclohexylamine
  • 2.0 g (6.8 mmol) of trans-1amino-4-dibenzylaminocyclohexane (see Example 2) was dissolved in 50 mL DMF and stirred for 48 h at RT with 1.6 g (7 mmol) of 1,5-dibromopentane and 2 g of potassium carbonate. The mixture was cooled, combined with water, extracted twice with 100 mL of dichloromethane, dried and the solvent was eliminated in vacuo. The residue is purified over a column (about 100 mL silica gel, about 500 mL ethyl acetate 80/methanol 20+1% conc. ammonia). The desired fractions were evaporated down in vacuo and crystallised from petroleum ether. Yield: 1.2 g (49%).
    • trans-4-piperidino-cyclohexylamine
  • 1.7 g (4.8 mmol) of trans-dibenzyl-4-piperidino-cyclohexylamine were dissolved in 35 mL MeOH and hydrogenated on 350 mg of Pd/C (10%) at 20° C. The solvent was eliminated in vacuo and the residue crystallised from ethanol and conc. HCl. Yield: 1.1 g (78%).
  • The cis isomer may be prepared analogously.
    • cis- and trans-4-(4-phenyl-piperazin-1-yl)-cyclohexylamine
  • Figure US20050014760A1-20050120-C00031
  • 4.1 g (25.3 mmol) of 4-dibenzylcyclohexanone was dissolved in 50 mL of dichloromethane and stirred for 12 h at RT with 7.4 g (25.3 mmol) of N-phenylpyperazine and 7.4 g (35 mmol) of NaBH(OAc)3. Then water and potassium carbonate were added, the org. phase was separated off, dried and the solvent was eliminated in vacuo. The residue was purified over a silica gel column (ethyl acetate 80/methanol 20+0.5% conc. ammonia). Yield: 1.7 g (15.8%) of cis-isomer and 0.27 (2.5%) of trans-isomer.
    • trans-4-(4-phenyl-piperazin-1-yl)-cyclohexylamine
  • 270 mg (0.61 mmol) of trans-dibenzyl-[4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-amine were dissolved in 5 mL MeOH and hydrogenated on 40 mg of Pd/C (10%) at 20-30° C. The solvent was eliminated in vacuo and the residue crystallised from ethanol and conc. HCl. Yield: 110 mg (69%).
  • The cis isomer may be prepared analogously.
    • cis- and trans-4-(4-cyclopropylmethyl-piperazin-1-yl)-cyclohexylamine
  • Figure US20050014760A1-20050120-C00032
  • 9.8 g (33.4 mmol) of 4-dibenzylcyclohexanone was dissolved in 100 mL dichloromethane and stirred for 12 h at RT with 5.6 g (40 mmol) of N-cyclopropylmethylpiperazine and 8.5 g (40 mmol) of NaBH(OAc)3. Then water and potassium carbonate were added, the org. phase was separated off, dried and the solvent was eliminated in vacuo. The residue was purified over a silica gel column (about 50 mL silica gel, about 3 L ethyl acetate 95/methanol 5+0.25% conc. ammonia. The appropriate fractions were evaporated down in vacuo. The faster eluting cis compound crystallised from ethyl acetate. The trans-compound was crystallised from ethanol+conc. HCl. Yield: 8.5 g (61%) cis-isomer and 2.2 (13%) trans-isomer.
    • cis-4-(4-cyclopropylmethyl-piperazin-1-yl)-cyclohexylamine
  • 8.5 g (20 mmol) of cis-dibenzyl-[4-(4-cyclopropylmethyl-piperazin-1-yl)-cyclohexyl]-amine were dissolved in 170 mL MeOH and hydrogenated on 1.7 g Pd/C (10%) at 30-50° C. The solvent was eliminated in vacuo and the residue was crystallised from ethanol and conc. HCl. Yield: 4.4 g (91%).
  • The trans-isomer may be prepared analogously.
    • SYNTHESIS OF THE EXAMPLES Example 152
  • 0.15 g of the compound Z10, 0.14 g TBTU, 0.13 mL DIPEA were dissolved in dichloromethane and stirred for 20 minutes at 25° C. Then 90 μL 1-(3-aminopropyl)-4-methylpiperazine was added and stirred for a further 2 hours at 25° C. The solution was then diluted with dichloromethane and extracted with water. The product was precipitated by the addition of petroleum ether, ether and ethyl acetate to the organic phase. Yield: 0.16 g of beige solid
    • Example 164
  • 0.10 g of the compound Z10, 0.1 g TBTU, 0.08 mL DIPEA were dissolved in 4 mL dichloromethane and stirred for 20 minutes at 25° C. Then 44 μL dimethylaminopropylamine were added and stirred for a further 2 hours at 25° C. The solution was then diluted with dichloromethane and extracted with water. The product was precipitated by the addition of petroleum ether, ether and acetone to the organic phase. Yield: 0.08 g yellow solid.
    • Example 242
  • 0.15 g of the compound Z10, 0.14 g TBTU, 0.13 mL DIPEA were dissolved in 5 mL dichloromethane and stirred for 20 minutes at 25° C. Then 75 μL 1-(2-aminoethyl)piperidine were added and stirred for a further 2 hours at 25° C. The solution was then diluted with dichloromethane and extracted with water. The product was precipitated by the addition of petroleum ether, ether and ethyl acetate to the organic phase. Yield: 0.14 g yellow solid.
    • Example 188
  • 0.1 g of the compound Z2, 0.09 g TBTU, 0.05 mL DIPEA were dissolved in 15 mL dichloromethane and stirred for 20 minutes at 25° C. Then 33 mg 1-methyl-4-aminopiperidin were added and the mixture was stirred for a further 3 hours at 25° C. The solution was extracted with 20 mL water, then evaporated down in vacuo. The product was crystallised using ether. Yield: 0.047 g of white crystals.
    • Example 203
  • 0.1 g of the compound Z2, 0.09 g TBTU, 0.5 mL DIPEA were dissolved in 15 mL dichloromethane and stirred for 30 minutes at 25° C. Then 50 mg 4-amino-1-benzylpiperidin were added and the mixture was stirred for a further 3 hours at 25° C. The solution was extracted with 20 mL water, then evaporated down in vacuo. Then the residue was chromatographed over silica gel and the isolated product was crystallised with ether. Yield: 0.015 g of white crystals.
    • Example 94
  • 0.17 g of the compound Z1, 0.19 g TBTU, 0.11 mL DIPEA were dissolved in 50 mL dichloromethane and stirred for 30 minutes at 25° C. Then 63 mg of 1-methyl-4-aminopiperidine were added and the mixture was stirred for a further 17 hours at 25° C. 50 mL of water and 1 g of potassium carbonate were added to the solution and the organic phase was separated off using a phase separation cartridge, then evaporated down in vacuo. Then the product was purified by silica gel chromatography and the purified product was crystallised with ether. Yield: 0.1 g of white crystals.
    • Example 95
  • 0.17 g of the compound Z1, 0.19 g TBTU, 0.11 mL DIPEA were dissolved in 50 mL dichloromethane and stirred for 30 minutes at 25° C. Then 77 mg of exo-3-β-amino-tropane were added and the mixture was stirred for a further 17 hours at 25° C. 50 mL of water and 1 g of potassium carbonate were added to the solution and the organic phase was separated off using a phase separation cartridge, then evaporated down in vacuo. Then the product was purified by silica gel chromatography and the purified product was crystallised with ether. Yield: 0.03 g of white crystals.
    • Example 46
  • 0.15 g of the compound Z3, 0.12 g TBTU, 0.12 mL DIPEA were dissolved in 5 mL dichloromethane and stirred for 30 minutes at 25° C. Then 50 mg 1-methyl-4-aminopiperidin were added and the mixture was stirred for a further 2.5 hours at 25° C. The solution was then extracted with water and then evaporated down. The residue was dissolved in warm ethyl acetate and crystallised from ether and petroleum ether. Yield: 0.025 g of white crystals. M.p.: 203° C. as the base
    • Example 80
  • 0.2 g of the compound Z8, 0.2 g of TBTU, 0.1 mL of DIPEA were dissolved in 10 mL dichloromethane and stirred for 30 minutes at 25° C. Then 100 mg of 1-methyl-4-aminopiperidine were added and the mixture was stirred for a further 17 hours at 25° C. The solution was then extracted with a dilute potassium carbonate solution and evaporated down. The residue was crystallised using ether. Yield: 0.12 g of white crystals
    • Example 190
  • 0.2 g of compound Z8, 0.2 g of TBTU, 0.3 mL of DIPEA were dissolved in 5 mL dichloromethane and stirred for 1 h at 25° C. Then 0.13 g of 4-amino-1-benzylpiperidine were added and the mixture was stirred for a further hour at 25° C. The solution was then diluted with 10 mL methylene chloride and extracted with 20 mL water. Then the product was purified over silica gel and crystallised from ethyl acetate and ether. Yield: 0.23 g of the compound Z8.
  • 0.23 g of the benzylamine Z8 are dissolved in 10 mL methanol, combined with 50 mg of Pd/C and hydrogenated under 3 bar for 3 h at 25° C. By adding petroleum ether and ethyl acetate white crystals are produced. These are chromatographed over silica gel and crystallised from ethyl acetate and ether. Yield: 0.075 g of white crystals.
    • Example 196
  • 0.1 g of compound Z10, 0.09 g of TBTU, 0.3 mL of DIPEA were dissolved in 4 mL of dichloromethane and stirred for 20 minutes at 25° C. Then 67 mg xx amine was added and stirred for a further 2 hours at 25° C. The solution was then diluted with dichloromethane and extracted with water. It was then chromatographed over silica gel and the residue was dissolved in acetone, combined with ethereal HCl and the precipitate formed was isolated. Yield: 0.09 g light yellow solid
    • Example 166
  • 0.1 g of the compound Z10, 0.11 g of TBTU, 0.14 mL of DIPEA were dissolved in 2 mL dimethylformamide and stirred for 3 h at 50° C. Then 55 mg of 4-morpholinomethylphenylamine was added. The reaction mixture was then cooled to ambient temperature within 17 h. Then the dimethylformamide was eliminated in vacuo, the residue was taken up in dichloromethane and extracted with water. It was then chromatographed over silica gel and the product crystallised from ethyl acetate and ether. Yield: 0.06 g yellowish crystals
    • Example 81
  • 0.2 g of the compound Z4, 0.2 g of TBTU, 0.1 mL of DIPEA were dissolved in 10 mL dichloromethane and stirred for 30 minutes at 25° C. Then 0.1 g of 1-methyl-4-aminopiperidine were added and the mixture was stirred for a further 17 hours at 25° C. The solution was then extracted with aqueous potassium carbonate solution and then evaporated down. The product was crystallised using ether. Yield: 0.16 g of white crystals.
    • Example 162
  • 0.1 g of the compound Z5, 0.07 g of TBTU, 0.15 mL of DIPEA were dissolved in 5 mL dichloromethane and stirred for 20 minutes at 25° C. Then 0.04 g 1-methyl-4-aminopiperidine were added and the mixture was stirred for a further 2 hours at 25° C. The solution was then diluted with 15 mL dichloromethane and extracted with 20 mL water. The residue was dissolved in MeOH and acetone, combined with 1 mL ethereal HCl and evaporated down. A crystalline product was produced using ether, ethyl acetate and a little MeOH. Yield: 0.1 g of white crystals.
    • Example 88
  • 0.1 g of the compound Z6, 0.12 g of TBTU, 0.12 mL of DIPEA were in 10 mL dichloromethane dissolved and stirred for 30 minutes at 25° C. Then 0.04 g of 1-methyl-4-aminopiperidine were added and the mixture was stirred for a further 2 hours at 25° C. The solution was then diluted with 10 mL dichloromethane and extracted with 10 mL water. A crystalline product was produced using ether, ethyl acetate and petroleum ether. Yield: 0.6 g of white crystals.
    • Example 89
  • 0.1 g of the compound Z6, 0.08 g of TBTU, 0.08 mL of DIPEA were dissolved in 10 mL dichloromethane and stirred for 30 minutes at 25° C. Then 37 μL g N,N-dimethyineopentanediamine were added and the mixture was stirred for a further 2 hours at 25° C. The solution was then diluted with 10 mL dichloromethane and extracted with 10 mL water. The product was then chromatographed over silica gel and crystallised from ethyl acetate, ether and petroleum ether. Yield: 0.005 g of white crystals.
    • Example 26
  • 0.15 g of the compound Z7, 0.16 g of TBTU, 1 mL of DIPEA were dissolved in 5 mL dichloromethane and stirred for 30 minutes at 25° C. Then 0.1 g 4-morpholinocyclohexylamine were added and the mixture was stirred for a further 17 hours at 25° C. The residue was then combined with 10 mL of 10% potassium carbonate solution, the precipitate was isolated and washed with water. It was then dissolved in dichloromethane and evaporated down again. The product was crystallised from ethyl acetate. Yield: 0.1 g of white crystals.
    • Example 9
  • 150 mg of the compound Z9 and 93 mg of amine were dissolved in 5 mL dichloromethane and stirred with 160 mg of TBTU and 1 mL of DIPEA for 12 h at RT. The solvent was eliminated in vacuo, the residue was combined with 10 mL of 10% potassium carbonate solution. The precipitate was suction filtered, washed with water, taken up in dichloromethane, dried and the solvent eliminated in vacuo. The residue was crystallised from ethyl acetate. Yield: 82.0 mg; m.p. 253° C. (as base).
    • Example 16
  • 150 mg of the compound Z8 and 73 mg of trans-4-piperidino-cyclohexylamine were dissolved in 5 mL dichloromethane and stirred with 160 mg (0.50 mmol) of TBTU and 1 mL of DIPEA for 12 h at RT. The solvent was eliminated in vacuo, the residue was combined with 10 mL of 10% potassium carbonate solution. The precipitate was suction filtered, washed with water, taken up in dichloromethane, dried and the solvent eliminated in vacuo. The residue was crystallised from ethyl acetate. Yield: 87.0 mg; m.p. 237° C. (as base).
    • Example 37
  • 100 mg of the compound Z9 and 42 mg of 3-amino-1-ethyl-pyrolidine were dissolved in 10 mL dichloromethane and stirred with 90 mg of TBTU and 0.5 mL of DIPEA for 12 h at RT. The solvent was eliminated in vacuo, the residue was combined with 10 mL of 10% potassium carbonate solution. The precipitate was suction filtered, washed with water, taken up in dichloromethane, dried and the solvent was eliminated in vacuo. The residue was crystallised from ethyl acetate/petroleum ether. Yield: 24.0 mg.
    • Example 120
  • 100 mg of the compound Z11 and 73 mg of 4-amino-1 tetrahydro-4H-pyran-4-yl-piperidine were dissolved in 10 mL dichloromethane and stirred with 90 mg of TBTU and 0.5 mL of DIPEA for 1 h at RT. The solvent was eliminated in vacuo, the residue was combined with 10 mL of 10% potassium carbonate solution. The precipitate was suction filtered, washed with water, taken up in dichloromethane, dried and the solvent was eliminated in vacuo. The residue was crystallised from ethyl acetate/petroleum ether. Yield: 89 mg.
    • Example 212
  • 150 mg of the compound Z5 and 150 mg of trans-4-(4-cyclopropylmethyl-piperazin-1-yl)-cyclohexylamine (as the hydrochloride) were dissolved in 5 mL of dichloromethane and stirred with 160 mg of TBTU and 2 mL of DIPEA for 2 h at RT. The solvent was eliminated in vacuo, the residue was combined with 10 mL of 10% potassium carbonate solution. The precipitate was suction filtered, washed with water, taken up in dichloromethane, dried and the solvent eliminated in vacuo. The residue was purified over a column (20 mL silica gel, 300 mL ethyl acetate 90/methanol 10+2% conc. ammonia). The appropriate fractions were evaporated down in vacuo and crystallised from ethyl acetate. Yield: 140 mg; m.p. 187° C. (as base).
    • Example 232
  • 390 mg of the compound Z11 and 240 mg of trans-4-(4-tbutyloxycarbonyl-piperazin-1-yl)-cyclohexylamine were dissolved in 2.5 mL of NMP and stirred with 482 mg of TBTU and 1 mL triethylamine for 2 h at RT. Then 100 mL of water and 200 mg of potassium carbonate were added, the precipitate was suction filtered, washed with water and purified through a silica gel column. The appropriate fractions were evaporated down in vacuo, dissolved in 2 mL dichloromethane, combined with 2 mL of trifluoroacetic acid and stirred for 2 h at RT, combined with another 100 ml of water and 200 mg potassium carbonate and the precipitate was suction filtered and washed with water. Then the precipitate was purified through a silica gel column. The appropriate fractions were evaporated down in vacuo and the residue was crystallised from ethanol and conc. hydrochloric acid. Yield: 95 mg; m.p. 291° C.
    • Example 213
  • 60 mg of the compound of Example 232 was dissolved in 10 mL ethyl acetate and stirred with 1 mL of acetic anhydride and 1 mL of triethylamine for 30 min. at RT. The solvent was eliminated in vacuo, the residue combined with water and ammonia, the crystals precipitated were suction filtered and washed with water and a little cold acetone. Yield: 40 mg; m.p.248° C.
    • Example 218
  • 1.2 g of the compound Z9 and 0.5 g of 1,4-dioxaspiro[4.5]dec-8-ylamine were dissolved in 20 mL dichloromethane and stirred with 1.28 g of TBTU and 4 mL of triethylamine for 12 h at RT. Then 50 mL of water and 0.5 g of potassium carbonate were added, the org. phase was separated off, dried and evaporated down in vacuo. The residue was crystallised from ethyl acetate, combined with 25 mL of 1 N hydrochloric acid and 20 mL of methanol and stirred for 30 min at 50° C.
  • The methanol was eliminated in vacuo, the precipitate was suction filtered, washed with water and dried.
  • The residue was taken up in 20 mL dichloromethane, stirred with 0.5 g of thiomorpholine and 0.5 g of NaBH(OAc)3 for 12 h at RT. Then water and potassium carbonate were added, the org. phase was separated off, dried and the solvent was eliminated in vacuo. The residue was purified over a silica gel column. The appropriate fractions were evaporated down in vacuo and the hydrochloride was precipitated with ethereal HCl. Yield: 86 mg of trans-isomer; amorphous powder.
    • Example 187
  • 200 mg of the compound Z3 in 5 mL dichloromethane was combined with 0.1 mL of diisopropylethylamine and 180 mg of TBTU and stirred for 30 min. Then 191 mg of 4-(4-methyl-piperazin-1-yl)-phenylamine were added and the mixture was stirred overnight. The reaction mixture was combined with water and the aqueous phase extracted with dichloromethane. The combined organic phases were dried over Na2SO4 and Z9 orated down. The residue was purified by column chromatography (eluant: dichloromethane/methanol 100:7).
  • Yield: 128 mg (light yellow crystals)
  • The compounds of formula (I) listed in Table 1, inter alia, are obtained analogously to the procedure described hereinbefore. The abbreviations X1, X2, X3, X4 and X5 used in Table 1 in each case denote a link to a position in the general formula shown under Table 1 instead of the corresponding groups R1, R2, R3, R4 and L-R5.
    TABLE 1
    Figure US20050014760A1-20050120-C00033
    Ex- Config. R1
    ample HELA H460VINC R1 R2 or R2 R3 R4 Ln—R5 m m.p
    1 0.046 0.604 H
    Figure US20050014760A1-20050120-C00034
         		R
    Figure US20050014760A1-20050120-C00035
    Figure US20050014760A1-20050120-C00036
    Figure US20050014760A1-20050120-C00037
    2 0.056 0.971 H
    Figure US20050014760A1-20050120-C00038
         		R
    Figure US20050014760A1-20050120-C00039
    Figure US20050014760A1-20050120-C00040
    Figure US20050014760A1-20050120-C00041
    3 0.061 H
    Figure US20050014760A1-20050120-C00042
         		R
    Figure US20050014760A1-20050120-C00043
         		H
    Figure US20050014760A1-20050120-C00044
    4 0.098 H
    Figure US20050014760A1-20050120-C00045
         		R
    Figure US20050014760A1-20050120-C00046
         		H
    Figure US20050014760A1-20050120-C00047
    5 0.052 0.863 H
    Figure US20050014760A1-20050120-C00048
         		R
    Figure US20050014760A1-20050120-C00049
    Figure US20050014760A1-20050120-C00050
    Figure US20050014760A1-20050120-C00051
    6 0.053 0.822 H
    Figure US20050014760A1-20050120-C00052
         		R
    Figure US20050014760A1-20050120-C00053
    Figure US20050014760A1-20050120-C00054
    Figure US20050014760A1-20050120-C00055
    7 0.084 0.865 H
    Figure US20050014760A1-20050120-C00056
         		R
    Figure US20050014760A1-20050120-C00057
    Figure US20050014760A1-20050120-C00058
    Figure US20050014760A1-20050120-C00059
    8 0.063 H
    Figure US20050014760A1-20050120-C00060
         		R
    Figure US20050014760A1-20050120-C00061
         		H
    Figure US20050014760A1-20050120-C00062
    9 0.057 0.207 H
    Figure US20050014760A1-20050120-C00063
         		R
    Figure US20050014760A1-20050120-C00064
    Figure US20050014760A1-20050120-C00065
    Figure US20050014760A1-20050120-C00066
         		253
    10 0.091 H
    Figure US20050014760A1-20050120-C00067
         		R
    Figure US20050014760A1-20050120-C00068
         		H
    Figure US20050014760A1-20050120-C00069
    11 0.086 1.300 H
    Figure US20050014760A1-20050120-C00070
         		R
    Figure US20050014760A1-20050120-C00071
         		H
    Figure US20050014760A1-20050120-C00072
    12 0.099 1.069 H
    Figure US20050014760A1-20050120-C00073
         		R
    Figure US20050014760A1-20050120-C00074
         		H
    Figure US20050014760A1-20050120-C00075
    13 0.026 1.320 H
    Figure US20050014760A1-20050120-C00076
         		R
    Figure US20050014760A1-20050120-C00077
    Figure US20050014760A1-20050120-C00078
    Figure US20050014760A1-20050120-C00079
    14 0.055 3.000 H
    Figure US20050014760A1-20050120-C00080
         		R
    Figure US20050014760A1-20050120-C00081
         		H
    Figure US20050014760A1-20050120-C00082
    15 0.020 1.000 H
    Figure US20050014760A1-20050120-C00083
         		R
    Figure US20050014760A1-20050120-C00084
    Figure US20050014760A1-20050120-C00085
    Figure US20050014760A1-20050120-C00086
         		231
    16 0.017 0.483 H
    Figure US20050014760A1-20050120-C00087
         		R
    Figure US20050014760A1-20050120-C00088
    Figure US20050014760A1-20050120-C00089
    Figure US20050014760A1-20050120-C00090
         		237
    17 0.024 0.730 H
    Figure US20050014760A1-20050120-C00091
         		R
    Figure US20050014760A1-20050120-C00092
    Figure US20050014760A1-20050120-C00093
    Figure US20050014760A1-20050120-C00094
    18 0.040 1.764 H
    Figure US20050014760A1-20050120-C00095
         		R
    Figure US20050014760A1-20050120-C00096
         		H
    Figure US20050014760A1-20050120-C00097
    19 0.013 0.747 H
    Figure US20050014760A1-20050120-C00098
         		R
    Figure US20050014760A1-20050120-C00099
    Figure US20050014760A1-20050120-C00100
    Figure US20050014760A1-20050120-C00101
         		254
    20 0.083 3.000 H
    Figure US20050014760A1-20050120-C00102
         		R
    Figure US20050014760A1-20050120-C00103
    Figure US20050014760A1-20050120-C00104
    Figure US20050014760A1-20050120-C00105
    21 0.009 0.488 H
    Figure US20050014760A1-20050120-C00106
         		R
    Figure US20050014760A1-20050120-C00107
    Figure US20050014760A1-20050120-C00108
    Figure US20050014760A1-20050120-C00109
    22 0.008 0.347 H
    Figure US20050014760A1-20050120-C00110
         		R
    Figure US20050014760A1-20050120-C00111
    Figure US20050014760A1-20050120-C00112
    Figure US20050014760A1-20050120-C00113
    23 0.013 0.679 H
    Figure US20050014760A1-20050120-C00114
         		R
    Figure US20050014760A1-20050120-C00115
    Figure US20050014760A1-20050120-C00116
    Figure US20050014760A1-20050120-C00117
    24 0.017 0.277 H
    Figure US20050014760A1-20050120-C00118
         		R
    Figure US20050014760A1-20050120-C00119
    Figure US20050014760A1-20050120-C00120
    Figure US20050014760A1-20050120-C00121
    25 0.038 1.000 H
    Figure US20050014760A1-20050120-C00122
         		R
    Figure US20050014760A1-20050120-C00123
    Figure US20050014760A1-20050120-C00124
    Figure US20050014760A1-20050120-C00125
         		254
    26 0.059 0.424 H
    Figure US20050014760A1-20050120-C00126
         		R
    Figure US20050014760A1-20050120-C00127
    Figure US20050014760A1-20050120-C00128
    Figure US20050014760A1-20050120-C00129
    27 0.014 0.164 H
    Figure US20050014760A1-20050120-C00130
         		R
    Figure US20050014760A1-20050120-C00131
    Figure US20050014760A1-20050120-C00132
    Figure US20050014760A1-20050120-C00133
         		292
    28 0.018 0.164 H
    Figure US20050014760A1-20050120-C00134
         		R
    Figure US20050014760A1-20050120-C00135
    Figure US20050014760A1-20050120-C00136
    Figure US20050014760A1-20050120-C00137
         		160
    29 0.049 1.000 H
    Figure US20050014760A1-20050120-C00138
         		R
    Figure US20050014760A1-20050120-C00139
    Figure US20050014760A1-20050120-C00140
    Figure US20050014760A1-20050120-C00141
         		251
    30 0.012 0.574 H
    Figure US20050014760A1-20050120-C00142
         		R
    Figure US20050014760A1-20050120-C00143
    Figure US20050014760A1-20050120-C00144
    Figure US20050014760A1-20050120-C00145
    31 0.023 3.000 H
    Figure US20050014760A1-20050120-C00146
         		R
    Figure US20050014760A1-20050120-C00147
         		H
    Figure US20050014760A1-20050120-C00148
    32 0.049 3.000 H
    Figure US20050014760A1-20050120-C00149
         		R
    Figure US20050014760A1-20050120-C00150
    Figure US20050014760A1-20050120-C00151
    Figure US20050014760A1-20050120-C00152
    33 0.097 3.000 H
    Figure US20050014760A1-20050120-C00153
         		R
    Figure US20050014760A1-20050120-C00154
         		H
    Figure US20050014760A1-20050120-C00155
    34 0.055 1.000 H
    Figure US20050014760A1-20050120-C00156
         		R
    Figure US20050014760A1-20050120-C00157
    Figure US20050014760A1-20050120-C00158
    Figure US20050014760A1-20050120-C00159
         		242
    35 0.088 1.000 H
    Figure US20050014760A1-20050120-C00160
         		R
    Figure US20050014760A1-20050120-C00161
    Figure US20050014760A1-20050120-C00162
    Figure US20050014760A1-20050120-C00163
         		213
    36 0.021 1.000 H
    Figure US20050014760A1-20050120-C00164
         		R
    Figure US20050014760A1-20050120-C00165
    Figure US20050014760A1-20050120-C00166
    Figure US20050014760A1-20050120-C00167
         		232
    37 0.072 0.762 H
    Figure US20050014760A1-20050120-C00168
         		R
    Figure US20050014760A1-20050120-C00169
    Figure US20050014760A1-20050120-C00170
    Figure US20050014760A1-20050120-C00171
         		160
    38 0.087 0.278 H
    Figure US20050014760A1-20050120-C00172
         		R
    Figure US20050014760A1-20050120-C00173
    Figure US20050014760A1-20050120-C00174
    Figure US20050014760A1-20050120-C00175
         		225
    39 0.075 1.000 H
    Figure US20050014760A1-20050120-C00176
         		R
    Figure US20050014760A1-20050120-C00177
         		H
    Figure US20050014760A1-20050120-C00178
    40 0.038 0.187 H
    Figure US20050014760A1-20050120-C00179
         		R
    Figure US20050014760A1-20050120-C00180
    Figure US20050014760A1-20050120-C00181
    Figure US20050014760A1-20050120-C00182
         		226
    41 0.083 3.000 H
    Figure US20050014760A1-20050120-C00183
         		R
    Figure US20050014760A1-20050120-C00184
    Figure US20050014760A1-20050120-C00185
    Figure US20050014760A1-20050120-C00186
    42 0.076 2.310 H
    Figure US20050014760A1-20050120-C00187
         		R
    Figure US20050014760A1-20050120-C00188
    Figure US20050014760A1-20050120-C00189
    Figure US20050014760A1-20050120-C00190
    43 0.094 3.000 X1—CH3
    Figure US20050014760A1-20050120-C00191
    Figure US20050014760A1-20050120-C00192
    Figure US20050014760A1-20050120-C00193
    Figure US20050014760A1-20050120-C00194
         		218
    44 0.009 0.204 H
    Figure US20050014760A1-20050120-C00195
         		R
    Figure US20050014760A1-20050120-C00196
         		H
    Figure US20050014760A1-20050120-C00197
    45 0.022 0.792 H
    Figure US20050014760A1-20050120-C00198
         		R
    Figure US20050014760A1-20050120-C00199
    Figure US20050014760A1-20050120-C00200
    Figure US20050014760A1-20050120-C00201
    46 0.012 0.208 H
    Figure US20050014760A1-20050120-C00202
         		R
    Figure US20050014760A1-20050120-C00203
    Figure US20050014760A1-20050120-C00204
    Figure US20050014760A1-20050120-C00205
         		203
    47 0.028 H
    Figure US20050014760A1-20050120-C00206
         		R
    Figure US20050014760A1-20050120-C00207
         		H
    Figure US20050014760A1-20050120-C00208
    48 0.083 3.000 H
    Figure US20050014760A1-20050120-C00209
         		R
    Figure US20050014760A1-20050120-C00210
         		H
    Figure US20050014760A1-20050120-C00211
    49 0.059 0.529 H
    Figure US20050014760A1-20050120-C00212
         		R
    Figure US20050014760A1-20050120-C00213
    Figure US20050014760A1-20050120-C00214
    Figure US20050014760A1-20050120-C00215
    50 0.081 0.436 H
    Figure US20050014760A1-20050120-C00216
         		R
    Figure US20050014760A1-20050120-C00217
    Figure US20050014760A1-20050120-C00218
    Figure US20050014760A1-20050120-C00219
    51 0.080 0.150 H
    Figure US20050014760A1-20050120-C00220
         		R
    Figure US20050014760A1-20050120-C00221
    Figure US20050014760A1-20050120-C00222
    Figure US20050014760A1-20050120-C00223
    52 0.079 0.153 H
    Figure US20050014760A1-20050120-C00224
         		R
    Figure US20050014760A1-20050120-C00225
    Figure US20050014760A1-20050120-C00226
    Figure US20050014760A1-20050120-C00227
    53 0.076 0.245
    Figure US20050014760A1-20050120-C00228
    Figure US20050014760A1-20050120-C00229
    Figure US20050014760A1-20050120-C00230
    Figure US20050014760A1-20050120-C00231
    Figure US20050014760A1-20050120-C00232
    54 0.031 0.226 H
    Figure US20050014760A1-20050120-C00233
         		R
    Figure US20050014760A1-20050120-C00234
    Figure US20050014760A1-20050120-C00235
    Figure US20050014760A1-20050120-C00236
    55 0.013 0.086 H
    Figure US20050014760A1-20050120-C00237
         		R
    Figure US20050014760A1-20050120-C00238
    Figure US20050014760A1-20050120-C00239
    Figure US20050014760A1-20050120-C00240
    56 0.064 0.324 H
    Figure US20050014760A1-20050120-C00241
         		R
    Figure US20050014760A1-20050120-C00242
    Figure US20050014760A1-20050120-C00243
    Figure US20050014760A1-20050120-C00244
    57 0.038 0.067 H
    Figure US20050014760A1-20050120-C00245
         		R
    Figure US20050014760A1-20050120-C00246
    Figure US20050014760A1-20050120-C00247
    Figure US20050014760A1-20050120-C00248
    58 0.010 0.023 H
    Figure US20050014760A1-20050120-C00249
         		R
    Figure US20050014760A1-20050120-C00250
    Figure US20050014760A1-20050120-C00251
    Figure US20050014760A1-20050120-C00252
    59 0.095 1.000 H
    Figure US20050014760A1-20050120-C00253
         		R
    Figure US20050014760A1-20050120-C00254
    Figure US20050014760A1-20050120-C00255
    Figure US20050014760A1-20050120-C00256
    60 0.041 0.189 H
    Figure US20050014760A1-20050120-C00257
         		R
    Figure US20050014760A1-20050120-C00258
    Figure US20050014760A1-20050120-C00259
    Figure US20050014760A1-20050120-C00260
    61 0.065 1.040
    Figure US20050014760A1-20050120-C00261
    Figure US20050014760A1-20050120-C00262
    Figure US20050014760A1-20050120-C00263
    Figure US20050014760A1-20050120-C00264
    Figure US20050014760A1-20050120-C00265
         		217
    62 0.058 0.538 H
    Figure US20050014760A1-20050120-C00266
         		R
    Figure US20050014760A1-20050120-C00267
    Figure US20050014760A1-20050120-C00268
    Figure US20050014760A1-20050120-C00269
         		259
    63 0.081 0.206 H
    Figure US20050014760A1-20050120-C00270
         		R
    Figure US20050014760A1-20050120-C00271
    Figure US20050014760A1-20050120-C00272
    Figure US20050014760A1-20050120-C00273
         		184
    64 0.064 0.894 H
    Figure US20050014760A1-20050120-C00274
         		R
    Figure US20050014760A1-20050120-C00275
    Figure US20050014760A1-20050120-C00276
    Figure US20050014760A1-20050120-C00277
         		175
    65 0.052 0.216 H
    Figure US20050014760A1-20050120-C00278
         		R
    Figure US20050014760A1-20050120-C00279
    Figure US20050014760A1-20050120-C00280
    Figure US20050014760A1-20050120-C00281
         		172
    66 0.064 0.250 H
    Figure US20050014760A1-20050120-C00282
         		R
    Figure US20050014760A1-20050120-C00283
    Figure US20050014760A1-20050120-C00284
    Figure US20050014760A1-20050120-C00285
         		164
    67 0.052 0.566 H
    Figure US20050014760A1-20050120-C00286
         		R
    Figure US20050014760A1-20050120-C00287
    Figure US20050014760A1-20050120-C00288
    Figure US20050014760A1-20050120-C00289
         		115
    68 0.092 1.242 H
    Figure US20050014760A1-20050120-C00290
         		R
    Figure US20050014760A1-20050120-C00291
         		H
    Figure US20050014760A1-20050120-C00292
    69 0.055 0.633 H
    Figure US20050014760A1-20050120-C00293
         		R
    Figure US20050014760A1-20050120-C00294
         		H
    Figure US20050014760A1-20050120-C00295
    70 0.092 1.000 H
    Figure US20050014760A1-20050120-C00296
         		R
    Figure US20050014760A1-20050120-C00297
         		H
    Figure US20050014760A1-20050120-C00298
    71 0.035 0.227 H
    Figure US20050014760A1-20050120-C00299
         		R
    Figure US20050014760A1-20050120-C00300
    Figure US20050014760A1-20050120-C00301
    Figure US20050014760A1-20050120-C00302
         		146
    72 0.050 H
    Figure US20050014760A1-20050120-C00303
         		R
    Figure US20050014760A1-20050120-C00304
    Figure US20050014760A1-20050120-C00305
    Figure US20050014760A1-20050120-C00306
    73 0.091 H
    Figure US20050014760A1-20050120-C00307
         		R
    Figure US20050014760A1-20050120-C00308
         		H
    Figure US20050014760A1-20050120-C00309
    74 0.043 H
    Figure US20050014760A1-20050120-C00310
         		R
    Figure US20050014760A1-20050120-C00311
    Figure US20050014760A1-20050120-C00312
    Figure US20050014760A1-20050120-C00313
    75 0.046 0.557 H
    Figure US20050014760A1-20050120-C00314
         		R
    Figure US20050014760A1-20050120-C00315
    Figure US20050014760A1-20050120-C00316
    Figure US20050014760A1-20050120-C00317
    76 0.068 H
    Figure US20050014760A1-20050120-C00318
         		R
    Figure US20050014760A1-20050120-C00319
    Figure US20050014760A1-20050120-C00320
    Figure US20050014760A1-20050120-C00321
    77 0.055 1.000 H
    Figure US20050014760A1-20050120-C00322
         		R
    Figure US20050014760A1-20050120-C00323
         		H
    Figure US20050014760A1-20050120-C00324
    78 0.035 0.610 H
    Figure US20050014760A1-20050120-C00325
         		R
    Figure US20050014760A1-20050120-C00326
         		H
    Figure US20050014760A1-20050120-C00327
    79 0.043 H
    Figure US20050014760A1-20050120-C00328
         		R
    Figure US20050014760A1-20050120-C00329
         		H
    Figure US20050014760A1-20050120-C00330
    80 0.038 0.286 H
    Figure US20050014760A1-20050120-C00331
         		R
    Figure US20050014760A1-20050120-C00332
    Figure US20050014760A1-20050120-C00333
    Figure US20050014760A1-20050120-C00334
    81 0.050 0.237 H
    Figure US20050014760A1-20050120-C00335
         		R
    Figure US20050014760A1-20050120-C00336
    Figure US20050014760A1-20050120-C00337
    Figure US20050014760A1-20050120-C00338
         		194
    82 0.083 1.580 H
    Figure US20050014760A1-20050120-C00339
         		R
    Figure US20050014760A1-20050120-C00340
    Figure US20050014760A1-20050120-C00341
    Figure US20050014760A1-20050120-C00342
    83 0.069 0.263 H
    Figure US20050014760A1-20050120-C00343
         		R
    Figure US20050014760A1-20050120-C00344
    Figure US20050014760A1-20050120-C00345
    Figure US20050014760A1-20050120-C00346
    84 0.015 0.312 H
    Figure US20050014760A1-20050120-C00347
         		R
    Figure US20050014760A1-20050120-C00348
    Figure US20050014760A1-20050120-C00349
    Figure US20050014760A1-20050120-C00350
    85 0.025 0.754 H
    Figure US20050014760A1-20050120-C00351
         		R
    Figure US20050014760A1-20050120-C00352
         		H
    Figure US20050014760A1-20050120-C00353
    86 0.038 0.024 H
    Figure US20050014760A1-20050120-C00354
         		R
    Figure US20050014760A1-20050120-C00355
    Figure US20050014760A1-20050120-C00356
    Figure US20050014760A1-20050120-C00357
    87 0.029 0.066 H
    Figure US20050014760A1-20050120-C00358
         		R
    Figure US20050014760A1-20050120-C00359
    Figure US20050014760A1-20050120-C00360
    Figure US20050014760A1-20050120-C00361
    88 0.020 1.018 H
    Figure US20050014760A1-20050120-C00362
         		R
    Figure US20050014760A1-20050120-C00363
    Figure US20050014760A1-20050120-C00364
    Figure US20050014760A1-20050120-C00365
    89 0.047 0.245 H
    Figure US20050014760A1-20050120-C00366
         		R
    Figure US20050014760A1-20050120-C00367
    Figure US20050014760A1-20050120-C00368
    Figure US20050014760A1-20050120-C00369
    90 0.032 0.137 H
    Figure US20050014760A1-20050120-C00370
         		R
    Figure US20050014760A1-20050120-C00371
    Figure US20050014760A1-20050120-C00372
    Figure US20050014760A1-20050120-C00373
    91 0.041 1.780 H
    Figure US20050014760A1-20050120-C00374
         		R
    Figure US20050014760A1-20050120-C00375
    Figure US20050014760A1-20050120-C00376
    Figure US20050014760A1-20050120-C00377
    92 0.043 H
    Figure US20050014760A1-20050120-C00378
         		R
    Figure US20050014760A1-20050120-C00379
         		H
    Figure US20050014760A1-20050120-C00380
         		181
    93 0.060 H
    Figure US20050014760A1-20050120-C00381
         		R
    Figure US20050014760A1-20050120-C00382
         		H
    Figure US20050014760A1-20050120-C00383
    94 0.018 0.510 H
    Figure US20050014760A1-20050120-C00384
         		R
    Figure US20050014760A1-20050120-C00385
    Figure US20050014760A1-20050120-C00386
    Figure US20050014760A1-20050120-C00387
         		178
    95 0.047 1.000 H
    Figure US20050014760A1-20050120-C00388
         		R
    Figure US20050014760A1-20050120-C00389
    Figure US20050014760A1-20050120-C00390
    Figure US20050014760A1-20050120-C00391
    96 0.011 0.577 H
    Figure US20050014760A1-20050120-C00392
         		R
    Figure US20050014760A1-20050120-C00393
    Figure US20050014760A1-20050120-C00394
    Figure US20050014760A1-20050120-C00395
         		203
    97 0.032 0.066 H
    Figure US20050014760A1-20050120-C00396
         		R
    Figure US20050014760A1-20050120-C00397
    Figure US20050014760A1-20050120-C00398
    Figure US20050014760A1-20050120-C00399
         		179
    98 0.077 1.319 H
    Figure US20050014760A1-20050120-C00400
         		R
    Figure US20050014760A1-20050120-C00401
    Figure US20050014760A1-20050120-C00402
    Figure US20050014760A1-20050120-C00403
    99 0.025 0.209 H
    Figure US20050014760A1-20050120-C00404
         		R
    Figure US20050014760A1-20050120-C00405
    Figure US20050014760A1-20050120-C00406
    Figure US20050014760A1-20050120-C00407
         		280
    100 0.058 0.124 H
    Figure US20050014760A1-20050120-C00408
         		R
    Figure US20050014760A1-20050120-C00409
    Figure US20050014760A1-20050120-C00410
    Figure US20050014760A1-20050120-C00411
         		233
    101 0.031 0.124 H
    Figure US20050014760A1-20050120-C00412
         		R
    Figure US20050014760A1-20050120-C00413
    Figure US20050014760A1-20050120-C00414
    Figure US20050014760A1-20050120-C00415
    102 0.006 0.053 H
    Figure US20050014760A1-20050120-C00416
         		R
    Figure US20050014760A1-20050120-C00417
    Figure US20050014760A1-20050120-C00418
    Figure US20050014760A1-20050120-C00419
    103 0.005 0.076 H
    Figure US20050014760A1-20050120-C00420
         		R
    Figure US20050014760A1-20050120-C00421
    Figure US20050014760A1-20050120-C00422
    Figure US20050014760A1-20050120-C00423
    104 0.041 0.133 H
    Figure US20050014760A1-20050120-C00424
         		R
    Figure US20050014760A1-20050120-C00425
    Figure US20050014760A1-20050120-C00426
    Figure US20050014760A1-20050120-C00427
    105 0.015 0.055 H
    Figure US20050014760A1-20050120-C00428
         		R
    Figure US20050014760A1-20050120-C00429
    Figure US20050014760A1-20050120-C00430
    Figure US20050014760A1-20050120-C00431
         		229
    106 0.025 1.000 H
    Figure US20050014760A1-20050120-C00432
         		R
    Figure US20050014760A1-20050120-C00433
    Figure US20050014760A1-20050120-C00434
    Figure US20050014760A1-20050120-C00435
         		213
    107 0.043 0.363 H
    Figure US20050014760A1-20050120-C00436
         		R
    Figure US20050014760A1-20050120-C00437
    Figure US20050014760A1-20050120-C00438
    Figure US20050014760A1-20050120-C00439
         		285
    108 0.016 1.000 H
    Figure US20050014760A1-20050120-C00440
         		R
    Figure US20050014760A1-20050120-C00441
    Figure US20050014760A1-20050120-C00442
    Figure US20050014760A1-20050120-C00443
    109 0.031 0.760 H
    Figure US20050014760A1-20050120-C00444
         		R
    Figure US20050014760A1-20050120-C00445
    Figure US20050014760A1-20050120-C00446
    Figure US20050014760A1-20050120-C00447
    110 0.027 0.122 H
    Figure US20050014760A1-20050120-C00448
         		R
    Figure US20050014760A1-20050120-C00449
    Figure US20050014760A1-20050120-C00450
    Figure US20050014760A1-20050120-C00451
         		278
    111 0.023 0.503 H
    Figure US20050014760A1-20050120-C00452
         		R
    Figure US20050014760A1-20050120-C00453
    Figure US20050014760A1-20050120-C00454
    Figure US20050014760A1-20050120-C00455
    112 0.075 0.345 H
    Figure US20050014760A1-20050120-C00456
         		R
    Figure US20050014760A1-20050120-C00457
    Figure US20050014760A1-20050120-C00458
    Figure US20050014760A1-20050120-C00459
         		264
    113 0.037 0.687 H
    Figure US20050014760A1-20050120-C00460
         		R
    Figure US20050014760A1-20050120-C00461
    Figure US20050014760A1-20050120-C00462
    Figure US20050014760A1-20050120-C00463
         		279
    114 0.064 0.766 H
    Figure US20050014760A1-20050120-C00464
         		R
    Figure US20050014760A1-20050120-C00465
    Figure US20050014760A1-20050120-C00466
    Figure US20050014760A1-20050120-C00467
         		234
    115 0.016 0.076 H
    Figure US20050014760A1-20050120-C00468
         		R
    Figure US20050014760A1-20050120-C00469
    Figure US20050014760A1-20050120-C00470
    Figure US20050014760A1-20050120-C00471
    116 0.006 0.174 H
    Figure US20050014760A1-20050120-C00472
         		R
    Figure US20050014760A1-20050120-C00473
    Figure US20050014760A1-20050120-C00474
    Figure US20050014760A1-20050120-C00475
    117 0.010 0.370 H
    Figure US20050014760A1-20050120-C00476
         		R
    Figure US20050014760A1-20050120-C00477
    Figure US20050014760A1-20050120-C00478
    Figure US20050014760A1-20050120-C00479
    118 0.010 0.279 H
    Figure US20050014760A1-20050120-C00480
         		R
    Figure US20050014760A1-20050120-C00481
    Figure US20050014760A1-20050120-C00482
    Figure US20050014760A1-20050120-C00483
    119 0.008 0.438 H
    Figure US20050014760A1-20050120-C00484
         		R
    Figure US20050014760A1-20050120-C00485
    Figure US20050014760A1-20050120-C00486
    Figure US20050014760A1-20050120-C00487
    120 0.014 0.374 H
    Figure US20050014760A1-20050120-C00488
         		R
    Figure US20050014760A1-20050120-C00489
    Figure US20050014760A1-20050120-C00490
    Figure US20050014760A1-20050120-C00491
         		154
    121 0.011 0.427 H
    Figure US20050014760A1-20050120-C00492
         		R
    Figure US20050014760A1-20050120-C00493
    Figure US20050014760A1-20050120-C00494
    Figure US20050014760A1-20050120-C00495
    122 0.009 0.261 H
    Figure US20050014760A1-20050120-C00496
         		R
    Figure US20050014760A1-20050120-C00497
    Figure US20050014760A1-20050120-C00498
    Figure US20050014760A1-20050120-C00499
    123 0.043 0.490 H
    Figure US20050014760A1-20050120-C00500
         		R
    Figure US20050014760A1-20050120-C00501
    Figure US20050014760A1-20050120-C00502
    Figure US20050014760A1-20050120-C00503
    124 0.006 0.391 H
    Figure US20050014760A1-20050120-C00504
         		R
    Figure US20050014760A1-20050120-C00505
    Figure US20050014760A1-20050120-C00506
    Figure US20050014760A1-20050120-C00507
    125 0.049 0.795 H
    Figure US20050014760A1-20050120-C00508
         		R
    Figure US20050014760A1-20050120-C00509
    Figure US20050014760A1-20050120-C00510
    Figure US20050014760A1-20050120-C00511
         		283
    126 0.051 0.742 H
    Figure US20050014760A1-20050120-C00512
         		R
    Figure US20050014760A1-20050120-C00513
    Figure US20050014760A1-20050120-C00514
    Figure US20050014760A1-20050120-C00515
         		238
    127 0.045 0.787 H
    Figure US20050014760A1-20050120-C00516
         		R
    Figure US20050014760A1-20050120-C00517
    Figure US20050014760A1-20050120-C00518
    Figure US20050014760A1-20050120-C00519
         		221
    128 0.015 0.282 H
    Figure US20050014760A1-20050120-C00520
         		R
    Figure US20050014760A1-20050120-C00521
    Figure US20050014760A1-20050120-C00522
    Figure US20050014760A1-20050120-C00523
         		257
    129 0.035 0.646 H
    Figure US20050014760A1-20050120-C00524
         		R
    Figure US20050014760A1-20050120-C00525
    Figure US20050014760A1-20050120-C00526
    Figure US20050014760A1-20050120-C00527
         		284
    130 0.015 0.091 H
    Figure US20050014760A1-20050120-C00528
         		R
    Figure US20050014760A1-20050120-C00529
    Figure US20050014760A1-20050120-C00530
    Figure US20050014760A1-20050120-C00531
         		236
    131 0.023 0.101 H
    Figure US20050014760A1-20050120-C00532
         		R
    Figure US20050014760A1-20050120-C00533
    Figure US20050014760A1-20050120-C00534
    Figure US20050014760A1-20050120-C00535
         		141
    132 0.062 1.000 H
    Figure US20050014760A1-20050120-C00536
         		R
    Figure US20050014760A1-20050120-C00537
    Figure US20050014760A1-20050120-C00538
    Figure US20050014760A1-20050120-C00539
         		268
    133 0.011 0.075 H
    Figure US20050014760A1-20050120-C00540
         		R
    Figure US20050014760A1-20050120-C00541
    Figure US20050014760A1-20050120-C00542
    Figure US20050014760A1-20050120-C00543
         		272
    134 0.015 0.063 H
    Figure US20050014760A1-20050120-C00544
         		R
    Figure US20050014760A1-20050120-C00545
    Figure US20050014760A1-20050120-C00546
    Figure US20050014760A1-20050120-C00547
         		319
    135 0.012 0.699 H
    Figure US20050014760A1-20050120-C00548
         		R
    Figure US20050014760A1-20050120-C00549
    Figure US20050014760A1-20050120-C00550
    Figure US20050014760A1-20050120-C00551
         		289
    136 0.041 0.821 H
    Figure US20050014760A1-20050120-C00552
         		R
    Figure US20050014760A1-20050120-C00553
    Figure US20050014760A1-20050120-C00554
    Figure US20050014760A1-20050120-C00555
         		201
    137 0.039 0.148 H
    Figure US20050014760A1-20050120-C00556
         		R
    Figure US20050014760A1-20050120-C00557
    Figure US20050014760A1-20050120-C00558
    Figure US20050014760A1-20050120-C00559
         		223
    138 0.043 1.137 H
    Figure US20050014760A1-20050120-C00560
         		R
    Figure US20050014760A1-20050120-C00561
    Figure US20050014760A1-20050120-C00562
    Figure US20050014760A1-20050120-C00563
         		217
    139 0.097 3.000 H
    Figure US20050014760A1-20050120-C00564
         		R
    Figure US20050014760A1-20050120-C00565
    Figure US20050014760A1-20050120-C00566
    Figure US20050014760A1-20050120-C00567
         		112
    140 0.029 1.970 H
    Figure US20050014760A1-20050120-C00568
         		R
    Figure US20050014760A1-20050120-C00569
    Figure US20050014760A1-20050120-C00570
    Figure US20050014760A1-20050120-C00571
         		215
    141 0.057 H
    Figure US20050014760A1-20050120-C00572
         		R
    Figure US20050014760A1-20050120-C00573
    Figure US20050014760A1-20050120-C00574
    Figure US20050014760A1-20050120-C00575
         		198
    142 0.030 H
    Figure US20050014760A1-20050120-C00576
         		R
    Figure US20050014760A1-20050120-C00577
    Figure US20050014760A1-20050120-C00578
    Figure US20050014760A1-20050120-C00579
         		192
    143 0.086 H
    Figure US20050014760A1-20050120-C00580
         		R
    Figure US20050014760A1-20050120-C00581
         		H
    Figure US20050014760A1-20050120-C00582
         		139
    144 0.044 H
    Figure US20050014760A1-20050120-C00583
         		R
    Figure US20050014760A1-20050120-C00584
         		H
    Figure US20050014760A1-20050120-C00585
         		191
    145 0.043 3.000 H
    Figure US20050014760A1-20050120-C00586
         		R
    Figure US20050014760A1-20050120-C00587
    Figure US20050014760A1-20050120-C00588
    Figure US20050014760A1-20050120-C00589
    146 0.066 0.966 H
    Figure US20050014760A1-20050120-C00590
         		R
    Figure US20050014760A1-20050120-C00591
    Figure US20050014760A1-20050120-C00592
    Figure US20050014760A1-20050120-C00593
    147 0.055 1.760 H
    Figure US20050014760A1-20050120-C00594
         		R
    Figure US20050014760A1-20050120-C00595
         		H
    Figure US20050014760A1-20050120-C00596
    148 0.087 H
    Figure US20050014760A1-20050120-C00597
         		R
    Figure US20050014760A1-20050120-C00598
    Figure US20050014760A1-20050120-C00599
    Figure US20050014760A1-20050120-C00600
    149 0.085 H
    Figure US20050014760A1-20050120-C00601
         		R
    Figure US20050014760A1-20050120-C00602
    Figure US20050014760A1-20050120-C00603
    Figure US20050014760A1-20050120-C00604
    150 0.043 H
    Figure US20050014760A1-20050120-C00605
         		R
    Figure US20050014760A1-20050120-C00606
         		H
    Figure US20050014760A1-20050120-C00607
    151 0.043 H
    Figure US20050014760A1-20050120-C00608
         		R
    Figure US20050014760A1-20050120-C00609
    Figure US20050014760A1-20050120-C00610
    Figure US20050014760A1-20050120-C00611
         		155
    152 0.081 H
    Figure US20050014760A1-20050120-C00612
         		R
    Figure US20050014760A1-20050120-C00613
    Figure US20050014760A1-20050120-C00614
    Figure US20050014760A1-20050120-C00615
         		147
    153 0.072 2.640 H
    Figure US20050014760A1-20050120-C00616
         		R
    Figure US20050014760A1-20050120-C00617
    Figure US20050014760A1-20050120-C00618
    Figure US20050014760A1-20050120-C00619
         		128
    154 0.097 H
    Figure US20050014760A1-20050120-C00620
         		R
    Figure US20050014760A1-20050120-C00621
         		H
    Figure US20050014760A1-20050120-C00622
    155 0.079 H
    Figure US20050014760A1-20050120-C00623
         		R
    Figure US20050014760A1-20050120-C00624
         		H
    Figure US20050014760A1-20050120-C00625
    156 0.048 0.481 H
    Figure US20050014760A1-20050120-C00626
         		R
    Figure US20050014760A1-20050120-C00627
    Figure US20050014760A1-20050120-C00628
    Figure US20050014760A1-20050120-C00629
         		173
    157 0.051 H
    Figure US20050014760A1-20050120-C00630
         		R
    Figure US20050014760A1-20050120-C00631
    Figure US20050014760A1-20050120-C00632
    Figure US20050014760A1-20050120-C00633
         		134
    158 0.043 0.536 H
    Figure US20050014760A1-20050120-C00634
         		R
    Figure US20050014760A1-20050120-C00635
    Figure US20050014760A1-20050120-C00636
    Figure US20050014760A1-20050120-C00637
         		230
    159 0.029 1.000 H
    Figure US20050014760A1-20050120-C00638
         		R
    Figure US20050014760A1-20050120-C00639
    Figure US20050014760A1-20050120-C00640
    Figure US20050014760A1-20050120-C00641
         		260
    160 0.037 0.728 H
    Figure US20050014760A1-20050120-C00642
         		R
    Figure US20050014760A1-20050120-C00643
    Figure US20050014760A1-20050120-C00644
    Figure US20050014760A1-20050120-C00645
         		193
    161 0.081 X1—CH3
    Figure US20050014760A1-20050120-C00646
    Figure US20050014760A1-20050120-C00647
    Figure US20050014760A1-20050120-C00648
    Figure US20050014760A1-20050120-C00649
         		199
    162 0.071 0.903 X1—CH3
    Figure US20050014760A1-20050120-C00650
    Figure US20050014760A1-20050120-C00651
    Figure US20050014760A1-20050120-C00652
    Figure US20050014760A1-20050120-C00653
         		254
    163 0.071 1.000 H
    Figure US20050014760A1-20050120-C00654
         		R
    Figure US20050014760A1-20050120-C00655
    Figure US20050014760A1-20050120-C00656
    Figure US20050014760A1-20050120-C00657
         		249
    164 0.030 0.975 H
    Figure US20050014760A1-20050120-C00658
         		R
    Figure US20050014760A1-20050120-C00659
    Figure US20050014760A1-20050120-C00660
    Figure US20050014760A1-20050120-C00661
    165 0.046 0.668 H
    Figure US20050014760A1-20050120-C00662
         		R
    Figure US20050014760A1-20050120-C00663
    Figure US20050014760A1-20050120-C00664
    Figure US20050014760A1-20050120-C00665
    166 H
    Figure US20050014760A1-20050120-C00666
         		R
    Figure US20050014760A1-20050120-C00667
    Figure US20050014760A1-20050120-C00668
    Figure US20050014760A1-20050120-C00669
    167 0.034 0.817 H
    Figure US20050014760A1-20050120-C00670
         		R
    Figure US20050014760A1-20050120-C00671
    Figure US20050014760A1-20050120-C00672
    Figure US20050014760A1-20050120-C00673
    168 0.042 0.088 H
    Figure US20050014760A1-20050120-C00674
         		R
    Figure US20050014760A1-20050120-C00675
    Figure US20050014760A1-20050120-C00676
    Figure US20050014760A1-20050120-C00677
    169 0.044 0.503 H
    Figure US20050014760A1-20050120-C00678
         		R
    Figure US20050014760A1-20050120-C00679
    Figure US20050014760A1-20050120-C00680
    Figure US20050014760A1-20050120-C00681
    170 0.045 0.427 H
    Figure US20050014760A1-20050120-C00682
         		R
    Figure US20050014760A1-20050120-C00683
    Figure US20050014760A1-20050120-C00684
    Figure US20050014760A1-20050120-C00685
         		170
    171 0.031 0.790 H
    Figure US20050014760A1-20050120-C00686
         		R
    Figure US20050014760A1-20050120-C00687
    Figure US20050014760A1-20050120-C00688
    Figure US20050014760A1-20050120-C00689
         		196
    172 0.020 0.772 H
    Figure US20050014760A1-20050120-C00690
         		R
    Figure US20050014760A1-20050120-C00691
    Figure US20050014760A1-20050120-C00692
    Figure US20050014760A1-20050120-C00693
         		166
    173 0.070 0.871 H
    Figure US20050014760A1-20050120-C00694
         		R
    Figure US20050014760A1-20050120-C00695
    Figure US20050014760A1-20050120-C00696
    Figure US20050014760A1-20050120-C00697
    174 0.000 0.155 H
    Figure US20050014760A1-20050120-C00698
         		R
    Figure US20050014760A1-20050120-C00699
    Figure US20050014760A1-20050120-C00700
    Figure US20050014760A1-20050120-C00701
    175 0.000 0.296 H
    Figure US20050014760A1-20050120-C00702
         		R
    Figure US20050014760A1-20050120-C00703
    Figure US20050014760A1-20050120-C00704
    Figure US20050014760A1-20050120-C00705
    176 0.000 0.301 H
    Figure US20050014760A1-20050120-C00706
         		R
    Figure US20050014760A1-20050120-C00707
    Figure US20050014760A1-20050120-C00708
    Figure US20050014760A1-20050120-C00709
    177 0.000 0.082 H
    Figure US20050014760A1-20050120-C00710
         		R
    Figure US20050014760A1-20050120-C00711
    Figure US20050014760A1-20050120-C00712
    Figure US20050014760A1-20050120-C00713
    178 0.000 1.000 H
    Figure US20050014760A1-20050120-C00714
         		R
    Figure US20050014760A1-20050120-C00715
    Figure US20050014760A1-20050120-C00716
    Figure US20050014760A1-20050120-C00717
    179 0.000 1.000 H
    Figure US20050014760A1-20050120-C00718
         		R
    Figure US20050014760A1-20050120-C00719
    Figure US20050014760A1-20050120-C00720
    Figure US20050014760A1-20050120-C00721
    180 0.000 0.147 H
    Figure US20050014760A1-20050120-C00722
         		R
    Figure US20050014760A1-20050120-C00723
    Figure US20050014760A1-20050120-C00724
    Figure US20050014760A1-20050120-C00725
         		136
    181 0.000 0.754 H
    Figure US20050014760A1-20050120-C00726
         		R
    Figure US20050014760A1-20050120-C00727
    Figure US20050014760A1-20050120-C00728
    Figure US20050014760A1-20050120-C00729
    182 H
    Figure US20050014760A1-20050120-C00730
         		R
    Figure US20050014760A1-20050120-C00731
    Figure US20050014760A1-20050120-C00732
    Figure US20050014760A1-20050120-C00733
    183 H
    Figure US20050014760A1-20050120-C00734
         		R
    Figure US20050014760A1-20050120-C00735
    Figure US20050014760A1-20050120-C00736
    Figure US20050014760A1-20050120-C00737
    184 H
    Figure US20050014760A1-20050120-C00738
         		R
    Figure US20050014760A1-20050120-C00739
    Figure US20050014760A1-20050120-C00740
    Figure US20050014760A1-20050120-C00741
    185 H
    Figure US20050014760A1-20050120-C00742
         		R
    Figure US20050014760A1-20050120-C00743
    Figure US20050014760A1-20050120-C00744
    Figure US20050014760A1-20050120-C00745
         		217
    186 H
    Figure US20050014760A1-20050120-C00746
         		R
    Figure US20050014760A1-20050120-C00747
    Figure US20050014760A1-20050120-C00748
    Figure US20050014760A1-20050120-C00749
         		287
    187 H
    Figure US20050014760A1-20050120-C00750
         		R
    Figure US20050014760A1-20050120-C00751
    Figure US20050014760A1-20050120-C00752
    Figure US20050014760A1-20050120-C00753
         		223
    188 H
    Figure US20050014760A1-20050120-C00754
         		R
    Figure US20050014760A1-20050120-C00755
    Figure US20050014760A1-20050120-C00756
    Figure US20050014760A1-20050120-C00757
         		161
    189 H
    Figure US20050014760A1-20050120-C00758
         		R
    Figure US20050014760A1-20050120-C00759
    Figure US20050014760A1-20050120-C00760
    Figure US20050014760A1-20050120-C00761
         		267
    190 H
    Figure US20050014760A1-20050120-C00762
         		R
    Figure US20050014760A1-20050120-C00763
    Figure US20050014760A1-20050120-C00764
    Figure US20050014760A1-20050120-C00765
    191 H
    Figure US20050014760A1-20050120-C00766
         		R
    Figure US20050014760A1-20050120-C00767
    Figure US20050014760A1-20050120-C00768
    Figure US20050014760A1-20050120-C00769
    192 H
    Figure US20050014760A1-20050120-C00770
         		R
    Figure US20050014760A1-20050120-C00771
    Figure US20050014760A1-20050120-C00772
    Figure US20050014760A1-20050120-C00773
    193 H
    Figure US20050014760A1-20050120-C00774
         		R
    Figure US20050014760A1-20050120-C00775
    Figure US20050014760A1-20050120-C00776
    Figure US20050014760A1-20050120-C00777
    194 H
    Figure US20050014760A1-20050120-C00778
         		R
    Figure US20050014760A1-20050120-C00779
    Figure US20050014760A1-20050120-C00780
    Figure US20050014760A1-20050120-C00781
    195 H
    Figure US20050014760A1-20050120-C00782
         		R
    Figure US20050014760A1-20050120-C00783
    Figure US20050014760A1-20050120-C00784
    Figure US20050014760A1-20050120-C00785
    196 H
    Figure US20050014760A1-20050120-C00786
         		R
    Figure US20050014760A1-20050120-C00787
    Figure US20050014760A1-20050120-C00788
    Figure US20050014760A1-20050120-C00789
    197 H
    Figure US20050014760A1-20050120-C00790
    Figure US20050014760A1-20050120-C00791
    Figure US20050014760A1-20050120-C00792
    Figure US20050014760A1-20050120-C00793
    198 H
    Figure US20050014760A1-20050120-C00794
         		R
    Figure US20050014760A1-20050120-C00795
    Figure US20050014760A1-20050120-C00796
         		301
    199 H
    Figure US20050014760A1-20050120-C00797
         		R
    Figure US20050014760A1-20050120-C00798
    Figure US20050014760A1-20050120-C00799
         		291
    200 H
    Figure US20050014760A1-20050120-C00800
         		R
    Figure US20050014760A1-20050120-C00801
    Figure US20050014760A1-20050120-C00802
    201 H
    Figure US20050014760A1-20050120-C00803
         		R
    Figure US20050014760A1-20050120-C00804
    Figure US20050014760A1-20050120-C00805
    202
    Figure US20050014760A1-20050120-C00806
    Figure US20050014760A1-20050120-C00807
    Figure US20050014760A1-20050120-C00808
    Figure US20050014760A1-20050120-C00809
    Figure US20050014760A1-20050120-C00810
    203 H
    Figure US20050014760A1-20050120-C00811
         		R
    Figure US20050014760A1-20050120-C00812
    Figure US20050014760A1-20050120-C00813
    Figure US20050014760A1-20050120-C00814
    204 H
    Figure US20050014760A1-20050120-C00815
         		R
    Figure US20050014760A1-20050120-C00816
    Figure US20050014760A1-20050120-C00817
    Figure US20050014760A1-20050120-C00818
    205 H
    Figure US20050014760A1-20050120-C00819
         		R
    Figure US20050014760A1-20050120-C00820
    Figure US20050014760A1-20050120-C00821
    Figure US20050014760A1-20050120-C00822
         		255
    206 H
    Figure US20050014760A1-20050120-C00823
         		R
    Figure US20050014760A1-20050120-C00824
    Figure US20050014760A1-20050120-C00825
    Figure US20050014760A1-20050120-C00826
         		190
    207 H
    Figure US20050014760A1-20050120-C00827
         		R
    Figure US20050014760A1-20050120-C00828
    Figure US20050014760A1-20050120-C00829
    Figure US20050014760A1-20050120-C00830
         		236
    208 H
    Figure US20050014760A1-20050120-C00831
         		R
    Figure US20050014760A1-20050120-C00832
    Figure US20050014760A1-20050120-C00833
    Figure US20050014760A1-20050120-C00834
         		192
    209 H
    Figure US20050014760A1-20050120-C00835
         		R
    Figure US20050014760A1-20050120-C00836
    Figure US20050014760A1-20050120-C00837
    Figure US20050014760A1-20050120-C00838
         		211
    210 H
    Figure US20050014760A1-20050120-C00839
         		R
    Figure US20050014760A1-20050120-C00840
    Figure US20050014760A1-20050120-C00841
    Figure US20050014760A1-20050120-C00842
         		210
    211 X1—CH3
    Figure US20050014760A1-20050120-C00843
    Figure US20050014760A1-20050120-C00844
    Figure US20050014760A1-20050120-C00845
    Figure US20050014760A1-20050120-C00846
         		182
    212 X1—CH3
    Figure US20050014760A1-20050120-C00847
    Figure US20050014760A1-20050120-C00848
    Figure US20050014760A1-20050120-C00849
    Figure US20050014760A1-20050120-C00850
         		187
    213 H
    Figure US20050014760A1-20050120-C00851
         		R
    Figure US20050014760A1-20050120-C00852
    Figure US20050014760A1-20050120-C00853
    Figure US20050014760A1-20050120-C00854
         		248
    214 H
    Figure US20050014760A1-20050120-C00855
         		R
    Figure US20050014760A1-20050120-C00856
    Figure US20050014760A1-20050120-C00857
    Figure US20050014760A1-20050120-C00858
         		338
    215 X1—CH3
    Figure US20050014760A1-20050120-C00859
         		R
    Figure US20050014760A1-20050120-C00860
    Figure US20050014760A1-20050120-C00861
    Figure US20050014760A1-20050120-C00862
         		232
    216 H
    Figure US20050014760A1-20050120-C00863
         		R
    Figure US20050014760A1-20050120-C00864
    Figure US20050014760A1-20050120-C00865
    Figure US20050014760A1-20050120-C00866
         		217
    217 H
    Figure US20050014760A1-20050120-C00867
         		R
    Figure US20050014760A1-20050120-C00868
    Figure US20050014760A1-20050120-C00869
    Figure US20050014760A1-20050120-C00870
         		139
    218 H
    Figure US20050014760A1-20050120-C00871
         		R
    Figure US20050014760A1-20050120-C00872
    Figure US20050014760A1-20050120-C00873
    Figure US20050014760A1-20050120-C00874
    219 H
    Figure US20050014760A1-20050120-C00875
         		R
    Figure US20050014760A1-20050120-C00876
    Figure US20050014760A1-20050120-C00877
    Figure US20050014760A1-20050120-C00878
         		298
    220 H
    Figure US20050014760A1-20050120-C00879
         		R
    Figure US20050014760A1-20050120-C00880
    Figure US20050014760A1-20050120-C00881
    Figure US20050014760A1-20050120-C00882
         		279
    221 H
    Figure US20050014760A1-20050120-C00883
         		R
    Figure US20050014760A1-20050120-C00884
    Figure US20050014760A1-20050120-C00885
    Figure US20050014760A1-20050120-C00886
         		336
    222 H
    Figure US20050014760A1-20050120-C00887
         		R
    Figure US20050014760A1-20050120-C00888
    Figure US20050014760A1-20050120-C00889
    Figure US20050014760A1-20050120-C00890
         		241
    223 1 H
    Figure US20050014760A1-20050120-C00891
         		R
    Figure US20050014760A1-20050120-C00892
    Figure US20050014760A1-20050120-C00893
    Figure US20050014760A1-20050120-C00894
    224 1.056 1 H
    Figure US20050014760A1-20050120-C00895
         		R
    Figure US20050014760A1-20050120-C00896
    Figure US20050014760A1-20050120-C00897
    Figure US20050014760A1-20050120-C00898
    225 1.18 1 H
    Figure US20050014760A1-20050120-C00899
         		R
    Figure US20050014760A1-20050120-C00900
         		H
    Figure US20050014760A1-20050120-C00901
    226 0.295 1 H
    Figure US20050014760A1-20050120-C00902
         		R
    Figure US20050014760A1-20050120-C00903
    Figure US20050014760A1-20050120-C00904
    Figure US20050014760A1-20050120-C00905
    227 0.853 0.946 H
    Figure US20050014760A1-20050120-C00906
         		R
    Figure US20050014760A1-20050120-C00907
    Figure US20050014760A1-20050120-C00908
    Figure US20050014760A1-20050120-C00909
    228 1 H
    Figure US20050014760A1-20050120-C00910
         		R
    Figure US20050014760A1-20050120-C00911
    Figure US20050014760A1-20050120-C00912
    Figure US20050014760A1-20050120-C00913
    229 0.381 H
    Figure US20050014760A1-20050120-C00914
         		R
    Figure US20050014760A1-20050120-C00915
    Figure US20050014760A1-20050120-C00916
    Figure US20050014760A1-20050120-C00917
    230 0.193 H
    Figure US20050014760A1-20050120-C00918
         		R
    Figure US20050014760A1-20050120-C00919
    Figure US20050014760A1-20050120-C00920
    Figure US20050014760A1-20050120-C00921
    231 0.17 H
    Figure US20050014760A1-20050120-C00922
         		R
    Figure US20050014760A1-20050120-C00923
    Figure US20050014760A1-20050120-C00924
    Figure US20050014760A1-20050120-C00925
    232 1 H
    Figure US20050014760A1-20050120-C00926
         		R
    Figure US20050014760A1-20050120-C00927
    Figure US20050014760A1-20050120-C00928
    Figure US20050014760A1-20050120-C00929
    233 H
    Figure US20050014760A1-20050120-C00930
         		R
    Figure US20050014760A1-20050120-C00931
    Figure US20050014760A1-20050120-C00932
    Figure US20050014760A1-20050120-C00933
    234 H
    Figure US20050014760A1-20050120-C00934
         		R
    Figure US20050014760A1-20050120-C00935
    Figure US20050014760A1-20050120-C00936
    Figure US20050014760A1-20050120-C00937
    235 H
    Figure US20050014760A1-20050120-C00938
         		R
    Figure US20050014760A1-20050120-C00939
    Figure US20050014760A1-20050120-C00940
    Figure US20050014760A1-20050120-C00941
    236 H
    Figure US20050014760A1-20050120-C00942
         		R
    Figure US20050014760A1-20050120-C00943
    Figure US20050014760A1-20050120-C00944
    Figure US20050014760A1-20050120-C00945
    237 0.012 1 H
    Figure US20050014760A1-20050120-C00946
         		R
    Figure US20050014760A1-20050120-C00947
    Figure US20050014760A1-20050120-C00948
    Figure US20050014760A1-20050120-C00949
    238 0.015 1 H
    Figure US20050014760A1-20050120-C00950
         		R
    Figure US20050014760A1-20050120-C00951
    Figure US20050014760A1-20050120-C00952
    Figure US20050014760A1-20050120-C00953
    239 0.051 0.07 H
    Figure US20050014760A1-20050120-C00954
         		R
    Figure US20050014760A1-20050120-C00955
    Figure US20050014760A1-20050120-C00956
    Figure US20050014760A1-20050120-C00957
    240 0.017 0.054 H
    Figure US20050014760A1-20050120-C00958
         		R
    Figure US20050014760A1-20050120-C00959
    Figure US20050014760A1-20050120-C00960
    Figure US20050014760A1-20050120-C00961
    241 0.044 0.093 H
    Figure US20050014760A1-20050120-C00962
         		R
    Figure US20050014760A1-20050120-C00963
    Figure US20050014760A1-20050120-C00964
    Figure US20050014760A1-20050120-C00965
    242 0.019 0.524 H
    Figure US20050014760A1-20050120-C00966
         		R
    Figure US20050014760A1-20050120-C00967
    Figure US20050014760A1-20050120-C00968
    Figure US20050014760A1-20050120-C00969
    243 0.018 0.975 H
    Figure US20050014760A1-20050120-C00970
         		R
    Figure US20050014760A1-20050120-C00971
    Figure US20050014760A1-20050120-C00972
    Figure US20050014760A1-20050120-C00973
    244 0.0115 H
    Figure US20050014760A1-20050120-C00974
         		R
    Figure US20050014760A1-20050120-C00975
    Figure US20050014760A1-20050120-C00976
    Figure US20050014760A1-20050120-C00977
  • As has been found, the compounds of general formula (I) are characterised by their wide range of applications in the therapeutic field. Particular mention should be made of those applications in which the inhibition of specific cell cycle kinases, particularly the inhibiting effect on the proliferation of cultivated human tumour cells but also the proliferation of other cells, such as endothelial cells, for example, plays a part.
  • As could be demonstrated by FACS analysis, the inhibition of proliferation brought about by the compounds according to the invention is mediated by the arrest of the cells, particularly at the G2/M phase of the cell cycle. The cells arrest, independently of the cells used, for a specific length of time in this phase of the cell cycle before programmed cell death is initiated. An arrest in the G2/M phase of the cell cycle is triggered, for example, by the inhibition of specific cell cycle kinases. Studies in model organisms such as Schizosaccharomyces pombe or Xenopus, or investigations in human cells have shown that the transition from the G2 phase to mitosis is regulated by the CDK1/cyclin B kinase (Nurse, 1990). This kinase, which is also known as the “mitosis promoting factor” (MPF), phosphorylates and thereby regulates a number of proteins, such as e.g. nuclear lamins, kinesin-like motor proteins, condensins and Golgi matrix proteins, which play an important part in the breakdown of the nuclear envelope, in centrosome separation, the formation of the mitotic spindle apparatus, chromosome condensation and the breakdown of the Golgi apparatus (Nigg. E., 2001). A murine cell line with a temperature-sensitive CDK1 kinase mutant shows a rapid breakdown of the CDK1 kinase and a subsequent arrest in the G2/M phase after a temperature increase (Th'ng et al., 1990). The treatment of human tumour cells with inhibitors against CDK1/cyclin B such as e.g. butyrolactone also leads to an arrest in the G2/M phase and subsequent apoptosis (Nishio, et al. 1996). Another kinase which is involved in the G2 and mitosis phase is polo-like kinase 1 (Plk1), which is responsible for the maturation of the centrosomes, for the activation of the phosphatase Cdc25C, as well as for the activation of the anaphase promoting complex (Glover et al., 1998, Qian, et al., 2001). The injection of Plk1 antibodies leads to a G2 arrest in untransformed cells whereas tumour cells arrest in the mitosis phase (Lane and Nigg, 1996). In addition, the protein kinase aurora B has been described as having an essential function during entry into mitosis. Aurora B phosphorylates histone H3 at Ser 1 and thereby initiates chromosome condensation (Hsu, J. Y. et al., 2000). A specific cell cycle arrest in the G2/M phase may, however, also be triggered e.g. by the inhibition of specific phosphatases such as e.g. Cdc25C (Russell and Nurse, 1986). Yeasts with a defective cdc25 gene arrest in the G2 phase, while overexpression of cdc25 leads to early entry into the mitosis phase (Russell and Nurse, 1987). However, an arrest in the G2/M phase can also be triggered by the inhibition of certain motor proteins, so-capped kinesins such as e.g. Eg5 (Mayer et al., 1999), or by agents which stabilise or destabilise microtubules (e.g. colchicin, taxol, etoposide, vinblastin, vincristin) (Schiff and Horwitz, 1980).
  • In view of their biological properties the compounds of general formula I according to the invention, their isomers and their physiologically acceptable salts are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation.
  • Such diseases include, for example: viral infections (e.g. HIV and Kaposi's sarcoma); inflammatory and autoimmune diseases (e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and/or parasitic infections; leukaemias, lymphoma and solid tumours; skin diseases (e.g. psoriasis); bone diseases; cardiovascular diseases (e.g. restenosis and hypertrophy). They are also suitable for protecting proliferating cells (e.g. hair, intestinal, blood and progenitor cells) from damage to their DNA caused by radiation, UV treatment and/or cytostatic treatment (Davis et al., 2001).
  • The new compounds may be used for the prevention, short-term or long-term treatment of the abovementioned diseases, also in combination with other active substances used for the same indications, e.g. cytostatics.
  • The activity of the compounds according to the invention was determined in the cytotoxicity test on cultivated human tumour cells and/or in a FACS analysis, for example on HeLaS3 cells. In both test methods, the compounds exhibited a good to very good activity, i.e. for example an EC50 value in the HeLaS3 cytotoxicity test of less than 5 μmol, generally less than 1 μmol.
  • Measurement of Cytotoxicity on Cultivated Human Tumour Cells
  • To measure the cytotoxicity on cultivated human tumour cells, cells of the cervical cancer tumour cell line HeLaS3 (obtained from American Type Culture Collection (ATCC)) in Ham's F12 Medium (Life Technologies) and 10% foetal calf serum (Life Technologies) were cultivated and harvested in the logarithmic growth phase. Then the HeLaS3 cells were placed in 96-well plates (Costar) at a density of 1000 cells per well and incubated overnight in an incubator (at 37° C. and 5% CO2), while on each plate 6 wells were filled only with medium (3 wells as a control of the medium, 3 wells for incubation with reduced AlamarBlue). The active substances were added to the cells in various concentrations (dissolved in DMSO; final concentration: 1%) (in each case as a triple measurement). After 72 hours' incubation, 20 μl of AlamarBlue (AccuMed International) were added to each well, and the cells were incubated for a further 7 hours. As a control, 20 μl of reduced Alamar Blue (AlamarBlue reagent which had been autoclaved for 30 min) were added to 3 wells. After 7 h incubation the colour change of the AlamarBlue reagent in the individual wells was determined in a Perkin Elmer fluorescence spectrophotometer (excitation 530 nm, emission 590 nm, slits 15, integrate time 0.1). The amount of AlamarBlue reagent reacted represents the metabolic activity of the cells. The relative cell activity was calculated as a percentage of the control (HeLa S3 cells without inhibitor) and the active substance concentration which inhibits the cell activity by 50% (IC50) was obtained. The values were calculated from the average of three individual measurements, correcting for the control value (medium control).
  • FACS Analysis
  • Propidium iodide (PI) binds stoichiometrically to double-stranded DNA, and is thus suitable for determining the percentage of cells in the G1, S and G2/M phase of the cell cycle on the basis of the cell DNA content. Cells in the G0 and G1 phase have a diploid DNA content (2N), whereas cells in G2 or mitosis have a 4N DNA content.
  • For PI staining, 0.4 million HeLaS3 cells were seeded, for example, on a 75 cm2 cell culture flask, and after 24 h either 1% DMSO was added as control or the substance was added in various concentrations (in 1% DMSO). The cells were incubated for 24 h with the substance or with DMSO, before the cells were washed with 2×PBS and detached with trypsin/EDTA. The cells were centrifuged (1000 rpm, 5 min, 4° C.), and the cell pellet was washed 2× with PBS, before the cells were resuspended in 0.1 ml of PBS. Then the cells were fixed with 80% ethanol for 16 hours at 4° C. or alternatively for 2 hours at −20° C. The fixed cells (106 cells) were centrifuged (1000 rpm, 5 min, 4° C.), washed with PBS and then centrifuged again. The cell pellet was resuspended in 2 ml of Triton X-100 in 0.25% PBS, and incubated for 5 min on ice, before 5 ml of PBS were added and the mixture was centrifuged again. The cell pellet was resuspended in 350 μl of PI stain solution (0.1 mg/ml of Raze A, 10 μg/ml of presidium iodide in 1×PBS). The cells were incubated for 20 min in the dark with the stain buffer before being transferred into sample measuring vessels for the FACS scan. The DNA measurement was carried out in a Becton Dickinson FACS Analyzer, with an argon laser (500 mW, emission 488 nm), and the DNA Cell Quest Program (BD). The logarithmic PI fluorescence was determined with a band-pass filter (BP 585/42). The cell populations in the individual phases of the cell cycle were quantified with the ModFit LT program of Becton Dickinson.
  • The compounds of general formula (I) may be used on their own or combined with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances. Suitable preparations include for example tablets, capsules, suppositories, solutions, particularly solutions for injection (s.c., i.v., i.m.) and infusion, syrups, emulsions or dispersible powders. The amount of pharmaceutically active compound in each case should be in the range from 0.1-90 wt. %, preferably 0.5-50 wt. % of the total composition, i.e. in amounts which are sufficient to achieve the dosage range given below. The doses specified may, if necessary, be given several times a day.
  • Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
  • Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
  • Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
  • Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, while if water is used as the diluent organic solvents may optionally be used as solubilisers or auxiliary solvents, and transferred into injection vials or ampoules or infusion bottles.
  • Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
  • Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
  • Suitable excipients may be, for example, water, pharmaceutically acceptable organic solvents, such as paraffins (e.g. petroleum fractions), oils of vegetable origin (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolin, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silica and silicates), sugar (e.g. glucose, lactose and dextrose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).
  • The preparations are administered in the usual way, preferably by oral or transdermal route, particularly preferably by oral route. When administered orally the tablets may, of course, contain additives, such as e.g. sodium citrate, calcium carbonate and dicalcium phosphate together with various additives, such as starch, preferably potato starch, gelatine and the like, in addition to the abovementioned carriers. Lubricants such as magnesium stearate, sodium laurylsulphate and talc may also be used to form tablets. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients.
  • For parenteral use, solutions of the active substances may be prepared using suitable liquid carrier materials.
  • The dosage for intravenous use is 1-1000 mg per hour, preferably between 5-500 mg per hour.
  • However, it may optionally be necessary to deviate from the amounts specified, depending on the body weight or method of administration, the individual response to the medication, the nature of the formulation used and the time or interval over which it is administered. Thus, in some cases, it may be sufficient to use less than the minimum quantity specified above, while in other cases the upper limit specified will have to be exceeded. When large amounts are administered it may be advisable to spread them over the day in a number of single doses.
  • The formulation examples that follow illustrate the present invention without restricting its scope:
    • EXAMPLES OF PHARMACEUTICAL FORMULATIONS
  • A) Tablets per tablet
    active substance 100 mg
    lactose 140 mg
    corn starch 240 mg
    polyvinylpyrrolidone  15 mg
    magnesium stearate  5 mg
    500 mg
  • The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.
    B) Tablets per tablet
    active substance  80 mg
    lactose  55 mg
    corn starch 190 mg
    microcrystalline cellulose  35 mg
    polyvinylpyrrolidone  15 mg
    sodium-carboxymethyl starch  23 mg
    magnesium stearate  2 mg
    400 mg
  • The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodiumcarboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
    C) Ampoule solution
    active substance 50 mg
    sodium chloride 50 mg
    water for inj. 5 ml
  • The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.

Claims (6)

1. A method of treating a disease or condition chosen from cancer, infections, inflammatory and autoimmune diseases, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of the formula (I),
Figure US20050014760A1-20050120-C00978
wherein
R1, R2 which are identical or different, denote hydrogen or optionally substituted C1-C6-alkyl,
or
R1 and R2 together denote a 2- to 5-membered alkyl bridge which optionally contain 1 to 2 heteroatoms,
R3 denotes hydrogen or a group selected from among optionally substituted C1-C12-alkyl, C2-C12-alkenyl, C2-C12-alkynyl and C6-C14-aryl, or
a group selected from among optionally substituted and/or bridged C3-C12-cycloalkyl, C3-C12-cycloalkenyl, C7-C12-polycycloalkyl, C7-C12-polycycloalkenyl, C5-C12-spirocycloalkyl, C3-C12-heterocycloalkyl which contains 1 to 2 heteroatoms, and C3-C12-heterocycloalkenyl which contains 1 to 2 heteroatoms, or
R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which optionally contain 1 heteroatom,
R4 denotes a group selected from among hydrogen, —CN, hydroxy, —NR6R7 and halogen, or
a group selected from among optionally substituted C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C5-alkyloxy, C2-C5-alkenyloxy, C2-C5-alkynyloxy, C1-C6-alkylthio, C1-C6-alkylsulphoxo and C1-C6-alkylsulphonyl,
L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, —C2-C4-alkyl-C6-C14-aryl, —C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms,
n denotes 0 or 1
m denotes 1 or 2
R5 denotes a group selected from among optionally substituted morpholinyl, piperidinyl, piperazinyl, piperazinylcarbonyl, pyrrolidinyl, tropenyl, R8-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, —NR8R9 and azacycloheptyl,
R6, R7 which are identical or different, denote hydrogen or C1-C4-alkyl, and
R8, R9 denote unsubstituted nitrogen substituents at R5, which are identical or different, denote either hydrogen or a group selected from among C1-C6-alkyl, —C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, —C1-C4-alkyl-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl,
optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
2. The method according to claim 1 wherein
L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, —C2-C4-alkyl-C6-C14-aryl, —C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms
n denotes 1
m denotes 1 or 2
R5 denotes a group which is bound to L via a nitrogen atom, selected from among optionally substituted morpholinyl, piperidinyl, R8-piperazinyl, pyrrolidinyl, tropenyl, R8-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, —NR8R9 and azacycloheptyl,
R8, R9 denote unsubstituted nitrogen substituents at R5, which are identical or different, hydrogen or a group selected from among C1-C6-alkyl, —C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, —C1-C4-alkyl-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl.
3. The method according to claim 1, wherein
L denotes a linker selected from among optionally substituted C2-C10-alkyl, C2-C10-alkenyl, C6-C14-aryl, —C2-C4-alkyl-C6-C14-aryl, —C6-C14-aryl-C1-C4-alkyl, optionally bridged C3-C12-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms
n denotes 0 or 1
m denotes 1 or 2
R5 denotes a group which is bound to L via a carbon atom, selected from among R8-piperidinyl, R8R9-piperazinyl, R8-pyrrolidinyl, R8-piperazinylcarbonyl, R8-tropenyl, R8-morpholinyl and R8-azacycloheptyl,
and
R8, R9 denote unsubstituted nitrogen substituents at R5, which are identical or different, hydrogen or a group selected from among C1-C6-alkyl, —C1-C4-alkyl-C3-C10-cycloalkyl, C3-C10-cycloalkyl, C6-C14-aryl, —C1-C4-alkyl-C6-C6-C14-aryl, pyranyl, pyridinyl, pyrimidinyl, C1-C4-alkyloxycarbonyl, C6-C14-arylcarbonyl, C1-C4-alkylcarbonyl, C6-C14-arylmethyloxycarbonyl, C6-C14-arylsulphonyl, C1-C4-alkylsulphonyl and C6-C14-aryl-C1-C4-alkylsulphonyl.
4. The method according to claim 3, wherein
R1, R2 which are identical or different, denote a group selected from among hydrogen, Me, Et, Pr, or
R1 and R2 together form a C2-C4-alkyl bridge.
5. The method according to claim 4, wherein
R3 denotes a group selected from among optionally substituted C1-C10-alkyl, C3-C7-cycloalkyl, C3-C6-heterocycloalkyl and C6-C14-aryl or
R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which optionally contain 1 to 2 heteroatoms,
R4 denotes a group selected from among hydrogen, OMe, OH, Me, Et, Pr, OEt, NHMe, NH2, F, CL, Br, O-propargyl, O-butynyl, CN, SMe, NMe2, CONH2, ethynyl, propynyl, butynyl and allyl,
and
L denotes a linker selected from among optionally substituted phenyl, phenylmethyl, cyclohexyl and branched C1-C6-alkyl.
6. The method according to any one of claims 1, 2, 3, 4 or 5 wherein the disease or condition is chosen from: HIV, Kaposi's sarcoma, colitis, arthritis, Alzheimer's disease, glomerulonephritis, wound healing, bacterial, fungal and/or parasitic infections; leukaemias, lymphoma, solid tumours, skin diseases, bone diseases and cardiovascular diseases.
US10/903,807 2003-02-26 2004-07-30 Methods of treating diseases or conditions using dihydropteridinone compounds Abandoned US20050014760A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/903,807 US20050014760A1 (en) 2003-02-26 2004-07-30 Methods of treating diseases or conditions using dihydropteridinone compounds
US11/219,945 US7786299B2 (en) 2003-02-26 2005-09-06 Methods for treating diseases or conditions using dihydropteridinone compounds
US12/129,728 US7816530B2 (en) 2003-02-26 2008-05-30 Piperazinyl compounds
US12/873,687 US8003786B2 (en) 2003-02-26 2010-09-01 Dihydropteridinone compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/374,876 US6861422B2 (en) 2003-02-26 2003-02-26 Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US10/903,807 US20050014760A1 (en) 2003-02-26 2004-07-30 Methods of treating diseases or conditions using dihydropteridinone compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/374,876 Continuation US6861422B2 (en) 2003-02-26 2003-02-26 Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/219,945 Continuation US7786299B2 (en) 2003-02-26 2005-09-06 Methods for treating diseases or conditions using dihydropteridinone compounds

Publications (1)

Publication Number Publication Date
US20050014760A1 true US20050014760A1 (en) 2005-01-20

Family

ID=32926261

Family Applications (7)

Application Number Title Priority Date Filing Date
US10/374,876 Expired - Lifetime US6861422B2 (en) 2003-02-26 2003-02-26 Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US10/909,008 Abandoned US20050014761A1 (en) 2003-02-26 2004-07-30 Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions
US10/903,807 Abandoned US20050014760A1 (en) 2003-02-26 2004-07-30 Methods of treating diseases or conditions using dihydropteridinone compounds
US11/219,945 Expired - Lifetime US7786299B2 (en) 2003-02-26 2005-09-06 Methods for treating diseases or conditions using dihydropteridinone compounds
US11/941,463 Expired - Lifetime US7750152B2 (en) 2003-02-26 2007-11-16 Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same
US12/129,728 Expired - Lifetime US7816530B2 (en) 2003-02-26 2008-05-30 Piperazinyl compounds
US12/873,687 Expired - Fee Related US8003786B2 (en) 2003-02-26 2010-09-01 Dihydropteridinone compounds

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/374,876 Expired - Lifetime US6861422B2 (en) 2003-02-26 2003-02-26 Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US10/909,008 Abandoned US20050014761A1 (en) 2003-02-26 2004-07-30 Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions

Family Applications After (4)

Application Number Title Priority Date Filing Date
US11/219,945 Expired - Lifetime US7786299B2 (en) 2003-02-26 2005-09-06 Methods for treating diseases or conditions using dihydropteridinone compounds
US11/941,463 Expired - Lifetime US7750152B2 (en) 2003-02-26 2007-11-16 Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same
US12/129,728 Expired - Lifetime US7816530B2 (en) 2003-02-26 2008-05-30 Piperazinyl compounds
US12/873,687 Expired - Fee Related US8003786B2 (en) 2003-02-26 2010-09-01 Dihydropteridinone compounds

Country Status (1)

Country Link
US (7) US6861422B2 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014761A1 (en) * 2003-02-26 2005-01-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US20060009457A1 (en) * 2004-07-09 2006-01-12 Boehringer Ingelheim International Gmbh New pyridodihydropyrazinones, process for their manufacture and use thereof as medicaments
US20060035902A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060041137A1 (en) * 2004-08-18 2006-02-23 Takeda San Diego, Inc. Kinase inhibitors
US20060046989A1 (en) * 2004-08-25 2006-03-02 Boehringer Ingelheim International Gmbh New dihydropteridione derivatives, process for their manufacture and their use as medicament
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060084650A1 (en) * 2004-10-15 2006-04-20 Qing Dong Kinase inhibitors
US20070117816A1 (en) * 2005-10-07 2007-05-24 Brown Jason W Kinase inhibitors
US20070208027A1 (en) * 2004-12-02 2007-09-06 Adil Duran Intermediate compounds for the manufacture of fused piperazin-2-one derivatives
US20080009482A1 (en) * 2006-07-06 2008-01-10 Astrazeneca Ab Novel compounds
US20080108812A1 (en) * 2004-08-25 2008-05-08 Matthias Grauert Dihydropteridione Intermediate Compounds
US20080177066A1 (en) * 2004-08-14 2008-07-24 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20090030004A1 (en) * 2006-02-08 2009-01-29 Guenter Linz Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US20090124628A1 (en) * 2004-06-21 2009-05-14 Boehringer Ingelheim International Gmbh 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
US20090143379A1 (en) * 2004-08-14 2009-06-04 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20090156557A1 (en) * 2007-04-18 2009-06-18 Takeda San Diego, Inc. Kinase inhibitors
US20100280037A1 (en) * 2007-08-03 2010-11-04 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US9956225B2 (en) 2013-07-26 2018-05-01 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
US8085962B2 (en) * 2004-09-01 2011-12-27 Bose Corporation Audio system for portable device
CN101083982A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
TW200626155A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AR051095A1 (en) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND ITS USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
CN101084207A (en) * 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0515478A (en) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc heterocyclic derivatives and their use as mediators of stearoyl coa desaturase
AU2005329423A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101083986A (en) * 2004-09-20 2007-12-05 泽农医药公司 Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (scd)
WO2006034279A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
BRPI0611187A2 (en) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc amino thiazide derivatives as inhibitors of human stearoyl coa desaturase
EP1989330A4 (en) * 2006-01-31 2009-10-21 Elan Pharm Inc Alpha-synuclein kinase
AU2012256410B2 (en) * 2006-02-08 2016-04-28 Boehringer Ingelheim International Gmbh Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation
DE602007008837D1 (en) * 2006-02-14 2010-10-14 Vertex Pharma AS PROTEIN KINASE INHIBITORS USEFUL DYHYDRODIAZEPINE
RU2478635C2 (en) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Heteroaryl compounds, compositions containing them and methods of treating with use of such compounds
EP2126105A4 (en) * 2007-02-20 2010-11-03 Anaptysbio Inc Somatic hypermutation systems
WO2009042711A1 (en) * 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CA2700979C (en) 2007-09-28 2017-06-20 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2009103010A2 (en) * 2008-02-13 2009-08-20 Elan Pharmaceuticals, Inc. Alpha-synuclein kinase
WO2010025073A1 (en) * 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
CN102020643A (en) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 dihydropteridine ketone derivative, and preparation method and medicinal application thereof
CN103492391A (en) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
CA2773742C (en) 2009-09-25 2017-12-05 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
BR112012029057A2 (en) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. leukemia compositions and treatment methods
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
JP5931933B2 (en) 2011-02-25 2016-06-08 武田薬品工業株式会社 N-substituted oxazinopteridines and oxazinopteridinones
US20130131069A1 (en) * 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
PL2723344T3 (en) * 2011-08-19 2016-03-31 Maria Clementine Martin Klosterfrau Vertriebsges Mbh Monoterpene-containing agent for combination therapy
US9006226B2 (en) 2012-02-23 2015-04-14 Boehringer Ingelheim International Gmbh Dihydropteridinones I
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
UY34893A (en) 2012-07-10 2014-02-28 Takeda Pharmaceutical DERIVATIVES OF AZAINDOL
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
EP3019493B1 (en) * 2013-07-09 2017-06-14 Bayer Pharma Aktiengesellschaft Modified bet-protein inhibiting dihydrochinoxalinones and dihydropyridopyrazinones
BR112016001457A2 (en) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
WO2015106012A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
EP3099171A4 (en) * 2014-01-31 2017-08-09 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
JP2017504651A (en) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Use of diazepan derivatives
RU2016134947A (en) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. DERIVATIVES OF DIAMINOPYRIMIDINE BENZENESULPHONE AND THEIR APPLICATION
MX2016009976A (en) 2014-01-31 2016-11-15 Dana Farber Cancer Inst Inc Diazepane derivatives and uses thereof.
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
JP2017526741A (en) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Diazepan derivatives and uses thereof
JP2017525759A (en) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Dihydropteridinone derivatives and uses thereof
WO2016069578A1 (en) 2014-10-27 2016-05-06 Tensha Therapeutics, Inc. Bromodomain inhibitors
CN107257800B (en) * 2014-12-23 2020-06-30 达纳-法伯癌症研究所股份有限公司 Method for inducing target protein degradation by bifunctional molecules
WO2016135046A1 (en) * 2015-02-24 2016-09-01 Academisch Medisch Centrum Inhibitors of raf1, mst1, and pkl1 for use in the treatment of a retrovirus
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
BR112018004617A2 (en) 2015-09-11 2018-09-25 Dana Farber Cancer Inst Inc thienotriazoldiazepines acetamide and uses thereof
RU2750164C2 (en) 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Cyanothienotriazolodiazepines and methods for their use
CR20180336A (en) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc BIVALENT BROMODOMINIUM INHIBITORS AND USES OF THE SAME
EP3601282B1 (en) 2017-03-30 2021-07-21 F. Hoffmann-La Roche AG Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5586865A (en) * 1996-03-08 1996-12-24 Micronics Computers Inc. Fan with transition chamber for providing enhanced convective flow
US5959837A (en) * 1998-04-02 1999-09-28 Ideal Electronics Inc. Heat-radiating structure for CPU
US5964279A (en) * 1997-02-10 1999-10-12 Fujikura Ltd. Cooler for electronic devices
US5982616A (en) * 1997-08-20 1999-11-09 Compaq Computer Corporation Electronic apparatus with plug-in heat pipe module cooling system
US6109340A (en) * 1997-04-30 2000-08-29 Nidec Corporation Heat sink fan
US6590770B1 (en) * 2002-03-14 2003-07-08 Modine Manufacturing Company Serpentine, slit fin heat sink device
US6704196B1 (en) * 2002-07-25 2004-03-09 Allied Systems Design, Inc. Flow-through cooling in-the-round system
US6711013B2 (en) * 2002-04-23 2004-03-23 Dell Products L.P. Active heat sink utilizing hot plug fans

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US29885A (en) * 1860-09-04 Improvement in harrows
NL8303657A (en) 1983-10-24 1985-05-17 Pharmachemie Bv SOLUTION, STABLE, AQUEOUS, AQUEOUS, CONTAINING SOLUTION OF CISPLATINE, AND METHOD OF PREPARING THEREOF.
DE3537761A1 (en) 1985-10-24 1987-04-30 Bayer Ag INFUSION SOLUTIONS OF 1-CYCLOPROPYL-6-FLUOR-1,4-DIHYDRO-4-OXO-7- (1-PIPERAZINYL) -QUINOLINE-3-CARBONIC ACID
ES2058527T3 (en) 1988-06-16 1994-11-01 Smith Kline French Lab CONDENSED DERIVATIVES OF PIRIMIDINE PROCEDURE AND INTERMEDIATE COMPOUNDS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
FR2645152B1 (en) 1989-03-30 1991-05-31 Lipha 3H-PTERIDINONES-4, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (en) 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CO4410191A1 (en) 1994-09-19 1997-01-09 Lilly Co Eli SYNTHESIS OF 3- [4- (2-AMINOETOXI) BENZOIL] -2-ARYL-6- HYDROXYBENZO [b] THIOPHENES
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
DK0825979T3 (en) 1995-05-19 2001-05-07 Novartis Ag Process for the preparation of aromatic nitro compounds
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
BR9711541A (en) 1996-09-23 1999-08-24 Lilly Co Eli Olanzapine dihydrate
CA2340180A1 (en) 1998-08-11 2000-02-24 Pfizer Products Inc. 1-aryl,-3-arylmethyl-1,8-naphthyridn-2(1h)-ones
MXPA02001108A (en) 1999-09-15 2002-08-20 Warner Lambert Co Pteridinones as kinase inhibitors.
TR200400220T4 (en) * 1999-12-10 2004-02-23 Pfizer Inc. As antagonists of bradykinin, 1,4-dihydropyridine compounds substituted with 5-membered heteroaryl.
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
DE10018783A1 (en) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Stable aqueous ciprofloxacin infusion solutions containing sulfuric acid as the stabilizing agent useful for the treatment of bacterial infections in humans and animals
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (en) 2000-11-22 2002-05-23 Bayer Ag Pharmaceutical kit containing repinotan, for use in acute treatment of neurological disorders such as stroke, including assay composition for determining body repinotan levels to optimize dosage
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
CN1551881A (en) 2001-09-04 2004-12-01 ���ָ��Ӣ��ķ�������Ϲ�˾ Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
BRPI0117198B1 (en) 2001-12-14 2018-03-13 Merck Serono S.A. USES OF COMPOSITION UNDERSTANDING A SELECTIVE INHIBITOR OF A PHOSPHODIESTERASE ISOFORM 4
JP2005538048A (en) 2002-05-03 2005-12-15 シエーリング アクチエンゲゼルシャフト Thiazolidinones, their production and use as pharmaceutical agents
US20060074119A1 (en) 2002-08-08 2006-04-06 Andrews Clarence W Iii Thiophene compounds
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EA008778B1 (en) 2003-02-26 2007-08-31 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Dihydropteridinones, method for the production and use thereof in the form of drugs
PL1605971T3 (en) 2003-03-26 2010-10-29 Wyeth Llc Immunogenic composition and methods
AU2004231342A1 (en) 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
DE102004002557A1 (en) 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of substituted pyrimido (5,4-d) pyrimidines for the treatment of respiratory diseases
JP2007517828A (en) 2004-01-17 2007-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of substituted pteridines to treat airway diseases
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
DE102004034623A1 (en) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 6-formyl-tetrahydropteridines, process for their preparation and their use as medicaments
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
EP1632493A1 (en) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridine derivatives, methods for their preparation and their use as drugs
JP2008510770A (en) 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pteridinone as a PLK inhibitor
EP1784406A1 (en) 2004-08-27 2007-05-16 Boehringer Ingelheim International GmbH Dihydropteridinones, process for their preparation and their use as drugs
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
CA2617589A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP2009529038A (en) * 2006-03-07 2009-08-13 アストラゼネカ・アクチエボラーグ Piperidine derivatives, processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5586865A (en) * 1996-03-08 1996-12-24 Micronics Computers Inc. Fan with transition chamber for providing enhanced convective flow
US5964279A (en) * 1997-02-10 1999-10-12 Fujikura Ltd. Cooler for electronic devices
US6109340A (en) * 1997-04-30 2000-08-29 Nidec Corporation Heat sink fan
US5982616A (en) * 1997-08-20 1999-11-09 Compaq Computer Corporation Electronic apparatus with plug-in heat pipe module cooling system
US5959837A (en) * 1998-04-02 1999-09-28 Ideal Electronics Inc. Heat-radiating structure for CPU
US6590770B1 (en) * 2002-03-14 2003-07-08 Modine Manufacturing Company Serpentine, slit fin heat sink device
US6711013B2 (en) * 2002-04-23 2004-03-23 Dell Products L.P. Active heat sink utilizing hot plug fans
US6704196B1 (en) * 2002-07-25 2004-03-09 Allied Systems Design, Inc. Flow-through cooling in-the-round system

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014761A1 (en) * 2003-02-26 2005-01-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions
US20100324288A1 (en) * 2003-02-26 2010-12-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinone Compounds
US20080293944A1 (en) * 2003-02-26 2008-11-27 Matthias Hoffmann Piperazinyl Compounds
US20060025411A1 (en) * 2003-02-26 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods for treating diseases or conditions using dihydropteridinone compounds
US7786299B2 (en) 2003-02-26 2010-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods for treating diseases or conditions using dihydropteridinone compounds
US8003786B2 (en) 2003-02-26 2011-08-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinone compounds
US20080171747A1 (en) * 2003-02-26 2008-07-17 Matthias Hoffman Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions
US7816530B2 (en) 2003-02-26 2010-10-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Piperazinyl compounds
US7750152B2 (en) 2003-02-26 2010-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7759347B2 (en) 2004-06-21 2010-07-20 Boehringer Ingelheim International Gmbh 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
US20090124628A1 (en) * 2004-06-21 2009-05-14 Boehringer Ingelheim International Gmbh 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
US8193188B2 (en) 2004-07-09 2012-06-05 Boehringer Ingelheim International Gmbh Methods of using pyridodihydropyrazinones
US20100029642A1 (en) * 2004-07-09 2010-02-04 Boehringer Ingelheim International Gmbh Methods of Using Pyridodihydropyrazinones
US7625899B2 (en) 2004-07-09 2009-12-01 Boehringer Ingelheim International Gmbh Pyridodihydropyraziones, process for their manufacture and use thereof as medicaments
US20060009457A1 (en) * 2004-07-09 2006-01-12 Boehringer Ingelheim International Gmbh New pyridodihydropyrazinones, process for their manufacture and use thereof as medicaments
US20090298840A1 (en) * 2004-08-14 2009-12-03 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US8138341B2 (en) 2004-08-14 2012-03-20 Boehringer Ingelheim International Gmbh Intermediate compounds useful for the manufacture of dihydropteridinones
US8591895B2 (en) 2004-08-14 2013-11-26 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US8445675B2 (en) 2004-08-14 2013-05-21 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US8202867B2 (en) 2004-08-14 2012-06-19 Boehringer Ingelheim International Gmbh Methods of using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide
US20060035902A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20080177066A1 (en) * 2004-08-14 2008-07-24 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US8143247B2 (en) 2004-08-14 2012-03-27 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20080221099A1 (en) * 2004-08-14 2008-09-11 Gerd Munzert Dihydropteridinones for the treatment of cancer diseases
US8138373B2 (en) 2004-08-14 2012-03-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US8058270B2 (en) 2004-08-14 2011-11-15 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US8034816B2 (en) 2004-08-14 2011-10-11 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20100249458A1 (en) * 2004-08-14 2010-09-30 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20100249412A1 (en) * 2004-08-14 2010-09-30 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20090143379A1 (en) * 2004-08-14 2009-06-04 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20090238828A1 (en) * 2004-08-14 2009-09-24 Boehringer Ingelheim International Gmbh Combinations for the Treatment of Diseases involving Cell Proliferation
US20090318457A1 (en) * 2004-08-14 2009-12-24 Boehringer Ingelheim International Gmbh Methods of Using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide
US20060041137A1 (en) * 2004-08-18 2006-02-23 Takeda San Diego, Inc. Kinase inhibitors
US20080113992A1 (en) * 2004-08-25 2008-05-15 Matthias Grauert Dihydropteridione Intermediate Compounds
US20090018333A1 (en) * 2004-08-25 2009-01-15 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US20080108812A1 (en) * 2004-08-25 2008-05-08 Matthias Grauert Dihydropteridione Intermediate Compounds
US20080319193A1 (en) * 2004-08-25 2008-12-25 Boehringer Ingelheim International Gmbh New dihydropteridione derivatives, process for their manufacture and their use as medicament
US7700769B2 (en) 2004-08-25 2010-04-20 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US7414053B2 (en) 2004-08-25 2008-08-19 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US7723517B2 (en) 2004-08-25 2010-05-25 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US20080319190A1 (en) * 2004-08-25 2008-12-25 Boehringer Ingelheim International Gmbh New dihydropteridione derivatives, process for their manufacture and their use as medicament
US20060046989A1 (en) * 2004-08-25 2006-03-02 Boehringer Ingelheim International Gmbh New dihydropteridione derivatives, process for their manufacture and their use as medicament
US20080319192A1 (en) * 2004-08-25 2008-12-25 Boehringer Ingelheim International Gmbh New dihydropteridione derivatives, process for their manufacture and their use as medicament
US7547780B2 (en) 2004-08-25 2009-06-16 Boehringer Ingelheim International Gmbh Dihydropteridione intermediate compounds
US7629460B2 (en) 2004-08-25 2009-12-08 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US7807831B2 (en) 2004-08-25 2010-10-05 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US20060084650A1 (en) * 2004-10-15 2006-04-20 Qing Dong Kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8288536B2 (en) 2004-10-15 2012-10-16 Takeda Pharmaceutical Company Limited Kinase inhibitors
USRE43115E1 (en) 2004-12-02 2012-01-17 Boehringer Ingelheim International Gmbh Process for the manufacture of fused piperazin-2-one derivatives
US7626019B2 (en) 2004-12-02 2009-12-01 Boehringer Ingelheim International Gmbh Intermediate compounds for the manufacture of fused piperazin-2-one derivatives
US20070213534A1 (en) * 2004-12-02 2007-09-13 Adil Duran Process for the Manufacture of fused piperazin-2-one derivatives
US20070213529A1 (en) * 2004-12-02 2007-09-13 Adil Duran Process for the Manufacture of fused piperazin-2-one derivatives
US20070213530A1 (en) * 2004-12-02 2007-09-13 Adil Duran Intermediate Compounds for the Manufacture of fused piperazin-2-one derivatives
US20070208027A1 (en) * 2004-12-02 2007-09-06 Adil Duran Intermediate compounds for the manufacture of fused piperazin-2-one derivatives
US20070213528A1 (en) * 2004-12-02 2007-09-13 Adil Duran Process for the Manufacture of Fused piperazin-2-one derivatives
US20070219369A1 (en) * 2004-12-02 2007-09-20 Adil Duran Process for the Manufacture of fused piperazin-2-one derivatives
US20070213531A1 (en) * 2004-12-02 2007-09-13 Adil Duran Process for the Manufacture of fused piperazin-2-one derivatives
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20070117816A1 (en) * 2005-10-07 2007-05-24 Brown Jason W Kinase inhibitors
US20090030004A1 (en) * 2006-02-08 2009-01-29 Guenter Linz Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8188086B2 (en) 2006-02-08 2012-05-29 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8664222B2 (en) 2006-02-08 2014-03-04 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US20080009482A1 (en) * 2006-07-06 2008-01-10 Astrazeneca Ab Novel compounds
US7709471B2 (en) 2006-07-06 2010-05-04 Astrazeneca Ab Compounds
US20090156557A1 (en) * 2007-04-18 2009-06-18 Takeda San Diego, Inc. Kinase inhibitors
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US20100280037A1 (en) * 2007-08-03 2010-11-04 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US9956225B2 (en) 2013-07-26 2018-05-01 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Also Published As

Publication number Publication date
US7786299B2 (en) 2010-08-31
US7816530B2 (en) 2010-10-19
US6861422B2 (en) 2005-03-01
US20080293944A1 (en) 2008-11-27
US20100324288A1 (en) 2010-12-23
US20080171747A1 (en) 2008-07-17
US7750152B2 (en) 2010-07-06
US20040176380A1 (en) 2004-09-09
US20060025411A1 (en) 2006-02-02
US20050014761A1 (en) 2005-01-20
US8003786B2 (en) 2011-08-23

Similar Documents

Publication Publication Date Title
US7786299B2 (en) Methods for treating diseases or conditions using dihydropteridinone compounds
CA2517020C (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
US8058270B2 (en) Dihydropteridinones for the treatment of cancer diseases
US7241889B2 (en) 6-formyl-tetrahydropteridines, process for their manufacture and use thereof as medicaments
US6806272B2 (en) Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US7547780B2 (en) Dihydropteridione intermediate compounds
US7759347B2 (en) 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
JP4484854B2 (en) Dihydropteridinone, process for its preparation and use in drug form

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION